Document:

FORM OF NOTE PURCHASE AGREEMENT

 Exhibit 10.1 
 NOTE PURCHASE AGREEMENT 
 OPKO Health, Inc. 

4400 Biscayne Blvd. 
 Miami, Florida 33137

 Ladies and Gentlemen: 
 Each of the undersigned (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”) hereby confirms its agreement with you as follows:

  

	 	1.	This Note Purchase Agreement (this “Agreement”) is made as of January 25, 2013, by and among OPKO Health, Inc., a Delaware corporation (the
“Company”), and each purchaser identified on the signature pages hereof (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). 

 

	 	2.	The Company and each Purchaser is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(2) of
the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “Commission”)
under the Securities Act. Each Purchaser is a “qualified institutional buyer” as defined in Rule 144A under the Securities Act or an “accredited investor” as defined in Regulation D. 

 

	 	3.	Subject to the terms and conditions of the Agreements (as defined below), the Company has authorized the issuance and sale for cash of up to $175,000,000 aggregate
principal amount of 3.00% Convertible Senior Notes (the “Notes”), to be issued pursuant to the Indenture, to be dated as of the Closing Date (as defined in Section 1.1 of Annex B hereto), among the Company and Wells
Fargo Bank, N.A. (the “Trustee”), as trustee thereunder, substantially in the form attached as Annex D hereto (the “Indenture”). As further described in the Indenture, the Notes shall mature February 1,
2033, bear interest on the unpaid balance thereof from the date thereof until the principal thereof shall have become due and payable (whether by acceleration or otherwise), and shall be convertible into shares of common stock, par value $0.01 per
share (the “Common Stock”) of the Company. 

  

	 	4.	The Company will, subject to the terms of this Agreement (including the terms and conditions set forth in Annex C), file one or more shelf registration
statements with respect to the resale of the Notes and Common Stock issuable upon conversion of the Notes, upon the terms and conditions hereinafter set forth. 

 

	 	5.	At the Closing, the Company will, subject to the terms of this Agreement (including the terms and conditions set forth in Annex B), issue and sell to the
Purchaser and the Purchaser will buy from the Company, upon the terms and conditions hereinafter set forth, the principal amount of Notes shown on the signature page hereof. 

	 	  	The Company is simultaneously entering into this same form of purchase agreement with certain other investors (the “Other Purchasers”) and expects to
complete sales of the Notes to them. The Purchaser and the Other Purchasers are hereinafter sometimes collectively referred to as the “Purchasers,” and this Agreement and the purchase agreements executed by the Other Purchasers are
hereinafter sometimes collectively referred to as the “Agreements.” 

  

	 	6.	The Notes purchased by each Purchaser will be delivered by electronic book-entry through the facilities of The Depository Trust Company (“DTC”), to an
account specified by each Purchaser set forth below, and will be released by the Trustee, at the written instruction of the Company, to such Purchaser at the Closing (as defined below). 

[Signature Pages to Follow] 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly
authorized representatives as of the day and year first above written. 
  

			
	 OPKO Health, Inc.

		
	 By:
	 	  

	 Name:
	 	  

	 Title
	 	  

  
 Signature Page

			
	 Print or Type:
	  	  

		  	 Name of Purchaser

(Individual or Institution)

		
		  	  

		  	Jurisdiction of Purchaser’s Executive Offices
		
		  	  

		  	Name of Individual representing Purchaser (if an Institution)
		
		  	  

		  	Title of Individual representing Purchaser (if an Institution)
		
		  	 $

		  	Principal amount of Notes to Be Purchased
		
		  	  

		  	Number of shares of Common Stock beneficially owned by Purchaser on the date hereof1

					
		
	Signature by:	  	Individual Purchaser or Individual representing Purchaser:
		
		  	  

			
		  	Address:	  	  

			
		  	Telephone:	  	  

			
		  	Facsimile:	  	  

			
		  	E-mail:	  	  

  

	1 	Include all shares of Common Stock, and all securities convertible into Common Stock on an as-converted basis, held by the Purchaser and all of its affiliates.

  
 Signature Page 

 SUMMARY INSTRUCTION SHEET FOR PURCHASER 

(To be read in conjunction with the entire Note Purchase Agreement.) 
 Complete the following items in the Note Purchase Agreement: 
  

	 	1.	Provide the information regarding the Purchaser requested on the signature page and Purchaser Questionnaire attached as Annex A to the Note Purchase Agreement
(the “Purchaser Questionnaire”). The Note Purchase Agreement must be executed by an individual authorized to bind the Purchaser. 

  

	 	2.	On or prior to 8:00 A.M. New York time on January 30, 2013, return an executed original Note Purchase Agreement or a facsimile transmission (or other electronic
transmission) thereof and the completed and executed Purchaser Questionnaire and a completed and executed tax withholding form to: 

 Charles Glazer 
 cglazer@jefferies.com 

Jefferies & Company, Inc. 
 520 Madison Avenue, 12th Floor 
 New York, New York 10022 

Purchasers who send a facsimile transmission (or other electronic transmission) on or prior to such deadline must also submit an original
via courier as soon thereafter as practicable. 
  

	 	3.	On or prior to 9:00 a.m., New York City time, on the Closing Date (as defined in the Purchase Agreement), Purchaser shall transfer the amount indicated below such
Purchaser’s name on the applicable signature page to the Note Purchase Agreement above the title “Principal Amount of Notes to be Purchased”, in United States dollars and in immediately available funds, by wire transfer to the account
of Jefferies & Company, Inc., as the Company’s closing agent (in such capacity, the “Closing Agent”). 

  

	 	4.	On or prior to 10:00 a.m., New York City time, on the Closing Date, each Purchaser must instruct its custodian(s) to post a DWAC Deposit request for such
Purchaser’s purchase of the Notes. 

  

	 	5.	Following the confirmation by the Closing Agent that the conditions set forth in the Purchase Agreement, other than with respect to the issuance of and delivery of the
Notes, have been satisfied or waived, (i) the Closing Agent shall disburse on the Closing Date funds received by the Closing Agent on behalf of the Company (net of the agreed amount of fees and expenses of the placement agents) by wire transfer
of immediately available funds to an account specified by the Company in accordance with the Company’s written wire instructions (which shall be provided to the Closing Agent by the Company at least one day prior to the Closing Date) and
(ii) the number of Notes purchased by each Purchaser (as specified on such Purchaser’s signature page hereof) to be issued and delivered by electronic book entry through the facilities of DTC to the account specified by such Purchaser in
its Purchaser Questionnaire will be released by the Trustee, at the written instruction of the Company, to such Purchaser upon receipt of Purchaser’s DWAC deposit request. 

 

	 	6.	Please note that all wire transfers must be sent to the following account and the name of the purchasing entity must be included in the wire:

  

			
	Wire Information
	ABA Number:	  	021000018
	Bank Name:	  	The Bank of New York
	Account Name:	  	Jefferies & Co., Inc.
	Account Number:	  	8900652772
	Re:	  	OPKO Health, Inc.

 The Closing Agent will notify each Purchaser once the transaction has closed. Each
Purchaser must instruct its custodian(s) to post a DWAC Deposit in order to receive Notes on the Closing Date. 
  

	 	7.	If you have any questions, please contact Charles Glazer at (212) 336-7360. 

 ANNEX A 
 OPKO HEALTH, INC. 
 PURCHASER QUESTIONNAIRE 

Pursuant to Section 1.4 of Annex B of the Agreement, please provide us with the following information: 

 

			
	Legal Name of Purchaser (i.e., Fund Name):	 	  

		
	Address of Purchaser:	 	  

		
		 	  

		
	 Attention:
	 	  

		
		 	  

		
	 Telephone Number:
	 	  

		
	 Fax Number:
	 	  

 NOMINEE/CUSTODIAN (Name in which the Notes and, if applicable, Conversion Shares are to be registered if different
than name of Purchaser): 
  

			
		 	  

		
	DTC Number:	 	  

		
	Tax I.D. Number or Social Security Number:	 	  

	(If acquired in the name of a nominee/custodian, the taxpayer I.D. number of such nominee/custodian)

 Person To Receive Copies of Transaction Documents: 

			
	 Name:
	 	  

		
	 Telephone Number:
	 	  

		
	 Email:
	 	  

		
	Operations Contacts:	 	  

		
	 Primary:
	 	  

		
	 Telephone Number:
	 	  

		
	 Email:
	 	  

		
		 	  

		
	 Secondary:
	 	  

		
	 Telephone Number:
	 	  

		
	 Email:
	 	  

 Tax Withholding Form Attached (indicate type): 

 

	 	 ̈	W-9 if U.S. Purchaser 

  

	 	 ̈	W-8 if Non-U.S. Purchaser 

 Each Purchaser must
be a “qualified institutional buyer” as defined in Rule 144A under the Securities Act or an “accredited investor” as defined in Rule 501 under the Securities Act. Indicate type as applicable to
Purchaser: 
  

	 	 ̈	Qualified Institutional Buyer 

  

	 	 ̈	Accredited Investor 

 *** Please note that if
you are sub-allocating to multiple funds, you must complete one of these forms for each fund. 

  
 Annex A-1

 ANNEX B 
 NOTE PURCHASE AGREEMENT 
 TERMS AND CONDITIONS 

1. Delivery of the Notes at the Closing; Termination. 

1.1 Closing. The closing of the purchase and sale of the Notes (the “Closing”) shall occur
at the offices of Akerman Senterfitt, One Southeast Third Avenue, 25th Floor, Miami, Florida 33131, on the third business day following the execution of the Agreements or on such later date or at such different location as the parties shall agree in writing, but not prior
to the date that the conditions for Closing set forth below have been satisfied or waived by the appropriate party (the date of such Closing being referred to herein as the “Closing Date”). 

1.2 Closing Deliveries. At the Closing, (a) the Purchaser shall pay, in immediately available funds, the full amount of the
purchase price for the Notes being purchased hereunder by wire transfer to the account specified by the Closing Agent and (b) delivery of the Notes, dated as of the Closing Date and in such principal amount as is being purchased by each
Purchaser, shall be made through the facilities of The Depository Trust Company (“DTC”) in accordance with DTC procedures for book-entry settlement representing the principal amount of Notes and bearing an appropriate legend
referring to the fact that the Notes were sold in reliance upon the exemption from registration under the Securities Act of 1933, as amended (the “Securities Act”), provided by Section 4(a)(2) thereof and Rule 506 thereunder.
The Closing Agent shall hold such certificates in escrow for the benefit of the Company until released by the Company for issuance and sale as provided in this Section 1.2. The name(s) in which the book-entry Notes are to be registered
are set forth in the Purchaser Questionnaire attached as Annex A to the Agreement. 
 1.3 Closing Mechanics.

 (a) One business day prior to the Closing, Jefferies & Company, Inc., (“Jefferies”) as closing
agent (in such capacity, the “Closing Agent”) will contact the contact person for the Purchaser to confirm the closing mechanics set forth herein. 
 (b) On or before 9:00 a.m., New York City time, on the Closing Date, the Purchaser will pay the full amount of the purchase price for the Notes being purchased hereunder to the Closing Agent as required
by Section 1.2. In the event that the Purchaser shall fail to deliver all or any portion of the purchase price for the Notes being purchased on or before 9:00 a.m., New York City time, on the Closing Date as required by
Section 1.2, the Closing Agent shall be permitted (but shall not be obligated), in its sole discretion, to fund the purchase price for the Notes being purchased on behalf of the Purchaser; provided, however, that the funding of the
purchase of any Notes by the Closing Agent pursuant to this Section 1.3(b) shall not relieve the Purchaser of any liability that it may have to the Company or the Closing Agent pursuant to this Agreement or for the breach of its
obligations under this Agreement. In any such case in which the Closing Agent, in its sole discretion, has elected to fund the purchase price for the Notes being purchased on behalf of the Purchaser, if the Purchaser has not fulfilled its

  
 Annex B-1.

 
obligation to purchase the Notes as set forth herein within two business days of the Closing Date, the Closing Agent shall thereafter be entitled to retain the certificates representing the Notes
and, if so requested by the Closing Agent, the Company shall transfer registration of such Notes to or as directed by the Closing Agent. 
 (c) In the event that the Closing Agent shall have funded the purchase of the Notes on behalf of the Purchaser under the circumstances set forth in clause (b) above, such Purchaser shall be
obligated to repay the Closing Agent in exchange for the release of the Notes to the Purchaser at a purchase price for the Notes equal to 100% of the purchase price for the Notes being purchased by such Purchaser, plus accrued interest from the
Closing Date; provided, however, that if the Closing Agent has funded such purchase on behalf of the Purchaser, and the Purchaser subsequently makes payment to the Closing Agent before 9:00 a.m., New York City time, on the Closing Date, the Purchase
Price shall equal the purchase price for such Notes plus an amount equal to the Closing Agent’s cost of intraday funds for such purchase. 
 (d) The receipt of funds by the Closing Agent from the Purchaser shall be deemed to be irrevocable instructions from such Purchaser to the Closing Agent that the conditions to the Closing have been
satisfied. 
 (e) Funds received by the Closing Agent on behalf of the Company pursuant to this Section 1 (or
funded by the Closing Agent in its sole discretion pursuant to Section 1.3(c)) will be held in trust and not as property or in the title of the Closing Agent. On the Closing Date, or as soon as reasonably practicable thereafter, the
Closing Agent shall disburse such funds (net of the agreed amount of fees and expenses of the placement agents) by wire transfer of immediately available funds in accordance with the Company’s written wire instructions (which shall be provided
to the Closing Agent at least one business day prior to the Closing Date), unless otherwise agreed to by the Company and the Closing Agent. 
 (f) Upon receipt of the purchase price from the Purchasers, the Closing Agent will cause the delivery of such funds to the Company, pursuant to written instructions from the Company (which shall be
provided to the Closing Agent at least one business day prior to the Closing Date). Immediately following the Company’s receipt of such funds, the Notes purchased by the Purchaser (as specified on the signature page hereof) will be issued by
the Company and delivered by electronic book-entry through the facilities of DTC to the account specified by the Purchaser on the Purchaser Questionnaire and will be released by the Trustee, at the written instruction of the Company, to such
Purchaser at the Closing and upon receipt of the Purchaser’s DWAC deposit request. 
 1.4 Conditions to the
Company’s Obligations. The Company’s obligation to complete the purchase and sale of the Notes and deliver such Notes by global certificate or by book-entry to the Purchaser at the Closing shall be subject to the following conditions,
any one or more of which may be waived by the Company: 
 (a) receipt by the Company of same-day funds in the full principal
amount of the Notes being purchased hereunder; 

  
 Annex B-2.

 (b) completion of the purchases and sales under the Agreements with the Other Purchasers;

 (c) the accuracy of the representations and warranties made by the Purchasers; and 

(d) receipt by the Company from the Purchaser of the fully completed questionnaire attached as Annex A to the Agreement.

 1.5 Conditions to the Purchaser’s Obligations. The Purchaser’s obligation to pay for the Notes shall be
subject to the following conditions, any one or more of which may be waived by the Purchaser: 
 (a) each of the
representations and warranties of the Company made herein shall be accurate as of the Closing Date and the Company shall have performed or satisfied in all material respects the covenants made by it in this Agreement; 

(b) the delivery to the Purchaser by counsel to the Company of a legal opinion substantially similar in substance to the form of opinion
attached as Annex E hereto; 
 (c) receipt by the Purchaser of a certificate executed by the chief executive officer and
the chief financial officer of the Company, dated as of the Closing Date, to the effect that the representations and warranties of the Company set forth herein are true and correct as of the date of this Agreement and as of such Closing Date and
that the Company has complied with all the agreements and satisfied all the conditions herein on its part to be performed or satisfied on or prior to such Closing Date; 
 (d) receipt by the Purchaser of a certificate of the Secretary of the Company, dated as of the Closing Date: 
 (i) certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this Agreement and the sale of the Notes and the issuance of the shares of Common
Stock issuable upon the conversion of the Notes (the “Conversion Shares”); 
 (ii) certifying the current
versions of the Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws of the Company; and 

(iii) certifying as to the signatures and authority of the persons signing this Agreement and related documents on behalf of the
Company; 
 (e) receipt by the Purchaser of a certificate of good standing for the Company for its jurisdiction of
incorporation; 
 (f) receipt by the Purchaser of a certificate from the Company’s transfer agent certifying the number of
shares of Common Stock outstanding as of the Closing Date; 

  
 Annex B-3.

 (g) the Common Stock shall continue to be listed on the NYSE as of the Closing Date; there
shall have been no suspensions in the trading of the Common Stock as of the Closing Date; and the Conversion Shares shall be approved for listing on the NYSE as of the Closing Date, subject to official notice of issuance; and 

(h) no injunction, restraining order, action or order of any nature by a governmental or regulatory authority shall have been issued,
taken or made or no action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority of competent jurisdiction that would, prior
to or as of the Closing Date, prevent or materially interfere with the consummation of the transactions contemplated by this Agreement. 
 2. Representations, Warranties and Covenants of the Company. The Company hereby represents and warrants to, and covenants with, the Purchaser as follows: 

2.1 Limitation on Offering Materials. The Company has not prepared, made, used, authorized, approved or distributed and
will not, and will not cause or allow its agents or representatives to, prepare, make, use, authorize, approve or distribute any written communication that constitutes an offer to sell or a solicitation of an offer to buy the Notes, or otherwise is
prepared to market the Notes, other than (i) the private placement memorandum collectively dated January 23, 2013 and January 25, 2013 (collectively, the “Placement Memorandum”) and (ii) the investor roadshow
presentation, without the written consent of Jefferies. 
 2.2 No Material Misstatement or Omission. The Placement
Memorandum, as of their respective dates thereof, did not and, at the time of each sale of the Notes, at the Closing Date, will not include any untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading. No injunction or order has been issued that either (i) asserts that the sale and issuance of the Notes is subject to the registration requirements of the
Securities Act or (ii) would prevent or suspend the issuance or sale of any of the Notes or the use of the Placement Memorandum in any jurisdiction. 
 2.3 SEC Reports. The information contained in the following documents (the “SEC Reports”), which are otherwise available through the Commission’s EDGAR system, as of
the dates thereof, did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were made, not
misleading: 
 (a) the Company’s Annual Report on Form 10-K for the year ended December 31, 2011; 

(b) the Company’s Quarterly Report on Form 10-Q for the quarters ended March 31, 2012, June 30, 2012 and
September 30, 2012; 
 (c) the Company’s Definitive Proxy Statement filed on April 27, 2012; 

  
 Annex B-4.

 (d) the Company’s Current Reports on Form 8-K filed on January 24,
2012, January 25, 2012, June 15, 2012, July 16, 2012, August 3, 2012, October 19, 2012, December 18, 2012, and January 9, 2013; 

(e) the description of the Company’s common stock contained in the Placement Memorandum; 

(f) all other documents, if any, filed by the Company (excluding the Current Reports on Form 8-K or the portions thereof furnished under
Item 2.02 or Item 7.01 of Form 8-K) with the Commission since December 31, 2011 pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). 

The SEC Reports, at the time they became effective or were filed with the Commission, as the case may be, complied in all material
respects with the requirements of the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder (the “1934 Act Rules and Regulations” and, together with the 1933 Act Rules and Regulations, the
“Rules and Regulations”). There are no contracts or other documents required to be described in such incorporated documents or to be filed as exhibits to such incorporated documents which have not been described or filed as
required, except that the acquisition agreements relating to the Company’s acquisitions of Prost-Data, Inc. (d/b/a OURLab) and Cytochroma Inc. (Markham Canada) have not been filed, and will be filed with a future SEC Report, as permitted by the
1934 Act Rules and Regulations. 
 2.4 Reporting Compliance. The Company is subject to, and is in full compliance
in all material respects with, the reporting requirements of Section 13 and Section 15(d), as applicable, of the Exchange Act. In the past 12 calendar months, the Company has filed all documents required to be filed by it prior to the date
hereof with the Commission pursuant to the reporting requirements of the Exchange Act and the 1934 Act Rules and Regulations. 

2.5 Authorization of the Notes and the Issuance of the Conversion Shares. The Notes have been duly authorized for issuance
and sale pursuant to this Agreement and the Conversion Shares have been duly and validly authorized and reserved for issuance and, when issued and delivered upon conversion of the Notes, will be validly issued, fully paid and nonassessable and will
conform to the description of the Common Stock contained in the Placement Memorandum, and the issuance and sale of the Notes and the issuance of the Conversion Shares upon conversion thereof is not subject to any preemptive rights, rights of first
refusal or other similar rights to subscribe for or purchase the Notes or the Conversion Shares. 
 2.6 No Material Adverse
Change. Except as otherwise disclosed in the SEC Reports, since December 31, 2011: (i) there has been no material adverse change, or any development that could reasonably be expected to result in a material adverse change, in
the condition, financial or otherwise, or in the earnings, business, operations or prospects, whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries, considered as one entity (any such change
is called a “Material Adverse Change”); (ii) the Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, not in the ordinary course of
business nor 

  
 Annex B-5.

 
entered into any material transaction or agreement not in the ordinary course of business; and (iii) there has been no dividend or distribution of any kind declared, paid or made by the
Company or, except for dividends paid to the Company or other subsidiaries, any of its subsidiaries on any class of capital stock or repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock. 

2.7 Independent Accountants. Ernst & Young LLP, who have expressed their opinion with respect to the financial
statements (which term as used in this Agreement includes the related notes thereto) and supporting schedules filed with the SEC are (i) independent registered public accountants with respect to the Company and its Subsidiaries as required by
the Securities Act and the Exchange Act, (ii) to the knowledge of the Company, in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X and (iii) to the knowledge of the
Company, a registered public accounting firm as defined by the Public Company Accounting Oversight Board (the “PCAOB”) whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn.

 2.8 Preparation of the Financial Statements. The financial statements filed with the SEC present fairly the
consolidated financial position of the Company and its subsidiaries as of and at the dates indicated and the results of their operations and cash flows for the periods specified, it being understood that unaudited interim financial statements are
subject to normal, year-end audit adjustments, which are not expected to be material. The supporting schedules filed with the SEC present fairly the information required to be stated therein. Such financial statements and supporting schedules have
been prepared in conformity with generally accepted accounting principles as applied in the United States applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. No other
financial statements or supporting schedules are required to be filed with the SEC. No person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to
Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with the SEC. All disclosures included in the SEC Reports
regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the SEC) comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities Act. 

2.9 Company’s Accounting System. The Company and each of its subsidiaries make and keep accurate books and records and
maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as
necessary to permit preparation of financial statements in conformity with generally accepted accounting principles as applied in the United States and to maintain accountability for assets; (iii) access to assets is permitted only in
accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
Except as disclosed in the SEC Reports and excluding the Company’s acquisitions of Prost-Data, Inc. (d/b/a OURLab) and Farmadiet Group Holdings, S.L., the Company is not aware of any 

  
 Annex B-6.

 
material weakness in the Company’s internal control over financial reporting (whether or not remediated) and since December 31, 2011, there has been no change in the Company’s
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. 

2.10 Incorporation and Good Standing of the Company and its Subsidiaries. Each of the Company and its subsidiaries has been duly
incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the
power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the SEC Reports and, in the case of the Company, to enter into and perform its obligations under this Agreement, except
where the failure to be in good standing would not reasonably be expected to result in a Material Adverse Change. Each of the Company and each subsidiary is duly qualified as a foreign corporation, partnership or limited liability company, as
applicable, to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified
or in good standing would not reasonably be expected to result in a Material Adverse Change. Except as disclosed in the SEC Reports, all of the issued and outstanding capital stock or other equity or ownership interests of each subsidiary have been
duly authorized and validly issued, are fully paid and nonassessable and are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. The Company does not
own or control, directly or indirectly, any corporation, association or other entity other than (i) the subsidiaries listed in Exhibit 21.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2011 and
(ii) such other entities omitted from Exhibit 21.1 as, when such omitted entities are considered in the aggregate as a single subsidiary, would not constitute a “significant subsidiary” within the meaning of Rule 1-02(w) of Regulation
S-X. 
 2.11 Capitalization and Other Capital Stock Matters. The authorized, issued and outstanding capital stock
of the Company is as set forth in the Placement Memorandum (other than for subsequent issuances, if any, pursuant to employee benefit plans described in the SEC Reports, upon the exercise of outstanding options or warrants described in the SEC
Reports or as described in Section 4(e)(ii) of this Agreement). All of the issued and outstanding shares of capital stock of the Company and each of its subsidiaries has been duly authorized and validly issued, are fully paid and nonassessable
and has been issued in compliance with federal and state securities laws. None of the outstanding shares of capital stock of the Company was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe
for or purchase securities of the Company. Except as otherwise set forth in the SEC Reports and excluding SciGen Limited, all of the outstanding shares of capital stock and other equity interests, as the case may be, of the Company’s
subsidiaries are owned by the Company, directly or indirectly through its subsidiaries, free and clear of all liens, encumbrances, equity or restrictions on transferability (other than those imposed by the Securities Act and the securities laws or
“Blue Sky” laws of certain U.S. state or non U.S. jurisdictions) or voting restrictions. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt
securities convertible into or exchangeable or 

  
 Annex B-7.

 
exercisable for, any capital stock of the Company or any of its subsidiaries other than those accurately described in the SEC Reports. The description of the Company’s stock option, stock
bonus and other stock plans or arrangements, and the options or other rights granted thereunder, set forth in the SEC Reports accurately and fairly presents the information required to be disclosed under the Securities Act or the Exchange Act, as
applicable, with respect to such plans, arrangements, options and rights. All grants of options to acquire Shares (each, a “Company Stock Option”) were validly issued and approved by the Board of Directors of the Company, a
committee thereof or an individual with authority duly delegated by the Board of Directors of the Company or a committee thereof. Grants of Company Stock Options were (i) made in material compliance with all applicable laws and (ii) as a
whole, made in material compliance with the terms of the plans under which such Company Stock Options were issued. There is no and has been no policy or practice of the Company to coordinate the grant of Company Stock Options with the release or
other public announcement of material information regarding the Company or its results of operations or prospects. Except as described in the SEC Reports, the Company has not sold or issued any shares of capital stock during the six-month period
preceding the date of the Placement Memorandum, including any sales pursuant to Rule 144A under, or Regulations D or S of, the Securities Act other than shares of capital stock issued pursuant to employee benefit plans, qualified stock options plans
or other employee compensation plans or pursuant to outstanding options, rights or warrants. 
 2.12 Stock Exchange
Listing. The Company’s common stock is registered pursuant to Section 12(b) of the Exchange Act and is listed on the New York Stock Exchange (“NYSE”), and the Company has taken no action designed to, or likely
to have the effect of, terminating the registration of the shares of common stock under the Exchange Act or delisting the shares of common stock from the NYSE, nor has the Company received any notification that the SEC or the NYSE is contemplating
terminating such registration or listing. 
 2.13 Non-Contravention of Existing Instruments; No Further Authorizations or
Approvals Required. Neither the Company nor any of its subsidiaries is in violation of its charter or by laws, partnership agreement or operating agreement or similar organizational document, as applicable (each, a “Charter
Document”), or is in default (or, with the giving of notice or lapse of time, would be in default) (“Default”) under any indenture, mortgage, loan or credit agreement, note, contract, franchise, lease or other instrument to
which the Company or any of its subsidiaries is a party or by which it or any of them may be bound (including, without limitation, any credit agreement, indenture, pledge agreement, security agreement or other instrument or agreement evidencing,
guaranteeing, securing or relating to indebtedness of the Company or any of its subsidiaries ), or to which any of the property or assets of the Company or any of its subsidiaries is subject (each, an “Existing Instrument”), except
for such Defaults as would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Change. The Company’s execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby
and by the Placement Memorandum and the issuance and sale of the Notes and the issuance of the Shares upon conversion thereof (i) have been duly authorized by all necessary corporate action and will not result in any violation of the provisions
of any Charter Document of the Company or any subsidiary, as applicable, (ii) will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of
any lien, charge or encumbrance upon any 

  
 Annex B-8.

 
property or assets of the Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument and (iii) will not result in any violation of
any law, administrative regulation or administrative or court decree applicable to the Company or any subsidiary or any of their properties (“Applicable Law”). No consent, approval, authorization or other order of, or registration
or filing with, any court or other governmental or regulatory authority or agency (each a “Governmental Authority”), is required for the Company’s execution, delivery and performance of this Agreement and consummation of the
transactions contemplated hereby and by the Placement Memorandum, except such as have been obtained or made by the Company and are in full force and effect under the Securities Act, applicable state securities or blue sky laws and from the Financial
Industry Regulatory Authority. As used herein, a “Debt Repayment Triggering Event” means any event or condition which gives, or with the giving of notice or lapse of time would give, the holder of any note, debenture or other
evidence of indebtedness (or any person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries. 

2.14 No Material Actions or Proceedings. There are no legal or governmental actions, suits or proceedings pending or, to the best
of the Company’s knowledge, threatened (i) against or affecting the Company or any of its subsidiaries, (ii) which have as the subject thereof any officer or director of, or property owned or leased by, the Company or any of its
subsidiaries or (iii) relating to environmental or discrimination matters, where in any such case (A) there is a reasonable possibility that such action, suit or proceeding will be determined adversely to the Company, such subsidiary or
such officer or director, (B) any such action, suit or proceeding, if so determined adversely, would reasonably be expected to result in a Material Adverse Change or adversely affect the consummation of the transactions contemplated by this
Agreement or (C) any such action, suit or proceeding is or would be material in the context of the sale of the Notes. No material labor dispute with the employees of the Company or any of its subsidiaries, or to the Company’s knowledge
with the employees of any principal supplier, manufacturer, customer or contractor of the Company, exists or, to the Company’s knowledge, is threatened or imminent, that if determined adversely would reasonably be expected to result in a
Material Adverse Change. 
 2.15 Intellectual Property Rights. The Company and its subsidiaries own or possess, or
can acquire or license on reasonable terms, sufficient trademarks, trade names, patent rights, copyrights, domain names, licenses, approvals, trade secrets and other similar rights (collectively, “Intellectual Property Rights”)
reasonably necessary to conduct their businesses as now conducted, except as such failure to own, possess, license, or acquire such rights would not result in a Material Adverse Change. Neither the Company nor any of its subsidiaries has received,
or has any reason to believe that it will receive, any notice of infringement or conflict with asserted Intellectual Property Rights of others. Except as would not result, individually or in the aggregate, in a Material Adverse Change, (A) to
the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any of the Intellectual Property Rights owned by the Company; (B) there is no pending or, to the knowledge of the Company, threatened
action, suit, proceeding or claim by others challenging the rights of the Company and its subsidiaries in or to any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim,
that would individually, or in 

  
 Annex B-9.

 
the aggregate, together with any other claims in this subsection 2.15, result in a Material Adverse Change; (C) the Intellectual Property Rights owned by the Company and its subsidiaries and
the Intellectual Property Rights licensed to the Company and its subsidiaries have not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part, and there is no pending or, to the knowledge of the Company,
threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim that would
individually, or in the aggregate, together with any other claims in this subsection 2.15, result in a Material Adverse Change; (D) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others
that the Company or its subsidiaries infringe, misappropriate or otherwise violate any Intellectual Property Rights or other proprietary rights of others, the Company and its subsidiaries have not received any written notice of such claim and the
Company is unaware of any other facts which would form a reasonable basis for any such claim that would individually, or in the aggregate, together with any other claims in this subsection 2.15 result in a Material Adverse Change; (E) to the
knowledge of the Company, there is no prior art that could reasonably be expected to render any patent held by or licensed to the Company or any subsidiary invalid or any U.S. patent application held by or licensed to the Company or any subsidiary
unpatentable which prior art was required to be disclosed to the U.S. Patent and Trademark Office during the prosecution of the applicable patent application and which was not so disclosed to the U.S. Patent and Trademark Office, the failure of
which to so disclose would individually, or in the aggregate, result in a Material Adverse Change; (F) to the knowledge of the Company, all prior art references relevant to the patentability of any pending claim of any patent applications
comprising or that have resulted in Intellectual Property Rights known to the Company, applicable inventor(s) or licensors, or any of their counsel during the prosecution of such patent applications that were required to be disclosed to the relevant
patent authority were so disclosed by the required time, except where the failure to so disclose would not individually, or in the aggregate, result in a Material Adverse Change, and, to the knowledge of the Company, neither the Company nor any such
inventor, licensor or counsel made any misrepresentation to, or omitted any material fact from, the relevant patent authority during such prosecution, which would individually, or in the aggregate, result in a Material Adverse Change; and
(G) to the knowledge of the Company, no employee of the Company or a subsidiary of the Company is in or has ever been in violation in any material respect of any term of any employment contract, patent disclosure agreement, invention assignment
agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee’s employment with the Company or a
subsidiary of the Company, or actions undertaken by the employee while employed with the Company or a subsidiary of the Company and would reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change. To the
knowledge of the Company, all material technical information developed by and belonging to the Company and its subsidiaries for which they have not sought, and do not intend to seek to patent or otherwise protect pursuant to applicable intellectual
property laws has been kept confidential or has been disclosed only under obligations of confidentiality. The Company is not a party to or bound by any options, licenses or agreements with respect to the Intellectual Property Rights of any other
person or entity that are required to be set forth in the SEC Reports and are not described in all material respects therein. None of the technology employed by the Company or 

  
 Annex B-10.

 
any of its subsidiaries has been obtained or is being used by the Company or any of its subsidiaries in violation of any contractual obligation binding on the Company or any of its subsidiaries
or any of its or its subsidiaries’ officers, directors or employees or otherwise in violation of the rights of any persons, except in each case for such violations that would not reasonably be expected to result in a Material Adverse Change.

 2.16 All Necessary Permits, etc. The Company and each subsidiary possess such valid and current certificates,
authorizations or permits issued by the appropriate state, federal or foreign regulatory agencies or bodies necessary to conduct their respective businesses as currently conducted and disclosed in the SEC Reports and the Placement Memorandum, except
for any of the foregoing that would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Change, and neither the Company nor any subsidiary has received, or has any reason to believe that it will receive, any
notice of proceedings relating to the revocation or modification of, or non-compliance with, any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would
reasonably be expected to result in a Material Adverse Change. 
 2.17 Title to Properties. Except as disclosed in the
SEC Reports, the Company and each of its subsidiaries has good and marketable title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in subsection 2.8 above, in each case free and
clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects, except as do not materially and adversely affect the value of such property and do not materially interfere with the use made or proposed to
be made of such property by the Company or such subsidiary. The real property, improvements, equipment and personal property held under lease by the Company or any subsidiary are held under valid and enforceable leases, with such exceptions as are
not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company or such subsidiary. 

2.18 Tax Law Compliance. The Company and its consolidated subsidiaries have filed all necessary federal, state and foreign
income and franchise tax returns or have properly requested extensions thereof and have paid all material taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine or penalty levied against any of them
except as may be being contested in good faith and by appropriate proceedings. The Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in subsection 2.8 above in respect of all federal, state
and foreign income and franchise taxes for all periods as to which the tax liability of the Company or any of its consolidated subsidiaries has not been finally determined. 
 2.19 Company Not an “Investment Company”. The Company has been advised of the rules and requirements under the Investment Company Act of 1940, as amended (the “Investment
Company Act”). The Company is not, and will not be, either after receipt of payment for the Notes or after the application of the proceeds therefrom, an “investment company” within the meaning of Investment Company Act and
will conduct its business in a manner so that it will not become subject to the Investment Company Act. 

  
 Annex B-11.

 2.20 Insurance. Each of the Company and its subsidiaries are insured by
recognized, financially sound and reputable institutions with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including, but not limited to, policies
covering real and personal property owned or leased by the Company and its subsidiaries against theft, damage, destruction, acts of vandalism and earthquakes and policies covering the Company and its subsidiaries for product liability claims and
clinical trial liability claims. The Company has no reason to believe that it or any subsidiary will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from
similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Change. Since March 27, 2007, neither of the Company nor any subsidiary has been denied
any insurance coverage material to the Company and its subsidiaries, taken as a whole, which it has sought or for which it has applied. 
 2.21 No Price Stabilization or Manipulation; Compliance with Regulation M. The Company has not taken, directly or indirectly, any action designed to or that might be reasonably expected to cause or
result in stabilization or manipulation of the price of the Notes or the Common Stock or any other “reference security” (as defined in Rule 100 of Regulation M under the 1934 Act (“Regulation M”)) whether to facilitate the
sale or resale of the Notes or otherwise, and has taken no action which would directly or indirectly violate Regulation M. 

2.22 Related Party Transactions. There are no business relationships or related-party transactions involving the Company or
any of its subsidiaries or any other person required to be described in the SEC Reports which have not been described as required. 
 2.23 Parties to Lock-Up Agreements. Each of the Company’s directors and executive officers has executed and delivered to Jefferies a lock-up agreement in the form of Annex F
hereto. If any additional persons shall become directors or executive officers of the Company prior to the end of the Lock-up Period (as defined therein), the Company shall cause each such person, prior to or contemporaneously with their
appointment or election as a director or executive officer of the Company, to execute and deliver to Jefferies an agreement in the form attached hereto as Annex F. 
 2.24 Statistical and Market-Related Data. The statistical, demographic and market-related data included in the SEC Reports and the Placement Memorandum are based on or derived from sources
that the Company believes to be reliable and accurate or represent the Company’s good faith estimates that are made on the basis of data derived from such sources. 
 2.25 No Unlawful Contributions or Other Payments. Neither the Company nor any of its subsidiaries nor, to the Company’s knowledge, any employee or agent of the Company or any
subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law or of the character required to be disclosed in the SEC Reports. 

2.26 Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting. Except as
set forth in the SEC Reports, the Company has established and maintains disclosure controls and procedures (as defined in Exchange Act 

  
 Annex B-12.

 
Rules 13a-15(e) and 15d-15(e)), which (i) are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the
Company’s principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared; (ii) have been
evaluated by management of the Company for effectiveness as of the end of the Company’s most recent fiscal quarter; and (iii) are effective in all material respects to perform the functions for which they were established, except as
disclosed in SEC Reports. Except as disclosed in SEC Reports, based on the most recent evaluation of its internal control over financial reporting, the Company is not aware of (i) any significant deficiencies or material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information or (ii) any fraud, whether or not
material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting. Except as set forth in the SEC Reports, the Company is not aware of any change in its internal control
over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. 

2.27 Compliance with Environmental Laws. Except as described in the SEC Reports and except as would not, singly or in the
aggregate, reasonably be expected to result in a Material Adverse Change, (i) neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or
rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without
limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes,
toxic substances, hazardous substances, petroleum or petroleum products (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous
Materials (collectively, “Environmental Laws”), (ii) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their
requirements, (iii) there are no pending or threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any
Environmental Law against the Company or any of its subsidiaries and (iv) there are no events or circumstances that might reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any
private party or governmental body or agency, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws. 
 2.28 Periodic Review of Costs of Environmental Compliance. In the ordinary course of its business, the Company conducts a periodic review of the effect of Environmental Laws on the business,
operations and properties of the Company and its subsidiaries, in the course of which it identifies and evaluates associated costs and liabilities (including, without limitation, any capital or operating expenditures required for clean-up, closure
of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints 

  
 Annex B-13.

 
on operating activities and any potential liabilities to third parties). On the basis of such review and the amount of its established reserves, the Company has reasonably concluded that such
associated costs and liabilities would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change. 
 2.29 ERISA Compliance. The Company and its subsidiaries and any “employee benefit plan” (as defined under the Employee Retirement Income Security Act of 1974, as amended,
and the regulations and published interpretations thereunder (collectively, “ERISA”)) established or maintained by the Company, its subsidiaries or their “ERISA Affiliates” (as defined below) are in compliance in
all material respects with ERISA. “ERISA Affiliate” means, with respect to the Company or a subsidiary, any member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of
1986, as amended, and the regulations and published interpretations thereunder (the “Code”) of which the Company or such subsidiary is a member. No “reportable event” (as defined under ERISA) has occurred or is
reasonably expected to occur with respect to any “employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates. No “employee benefit plan” established or maintained by the
Company, its subsidiaries or any of their ERISA Affiliates, if such “employee benefit plan” were terminated, would have any “amount of unfunded benefit liabilities” (as defined under ERISA). Neither the Company, its
subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any “employee benefit plan” or
(ii) Sections 412, 4971, 4975 or 4980B of the Code. Each “employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be qualified under
Section 401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification. 
 2.30 Brokers. Except for fees to be paid to Jefferies and Ladenburg Thalmann & Co. Inc. (“Ladenburg”), there is no broker, finder or other party that is entitled to
receive from the Company any brokerage or finder’s fee or other fee or commission as a result of any transactions contemplated by this Agreement. 
 2.31 No Outstanding Loans or Other Extensions of Credit. Since the adoption of Section 13(k) of the Exchange Act, neither the Company nor any of its subsidiaries has extended or maintained
credit, arranged for the extension of credit, or renewed any extension of credit, in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company and/or such subsidiary except for such extensions of
credit as are expressly permitted by Section 13(k) of the Exchange Act. 
 2.32 Compliance with Laws. The
Company has not been advised, and has no reason to believe, that it and each of its subsidiaries are not conducting business in compliance with all applicable laws, rules and regulations of the jurisdictions in which it is conducting business,
except where failure to be so in compliance would not reasonably be expected to result in a Material Adverse Change. Except as disclosed in the SEC Reports, the Company has not received any FDA Form 483, notice of adverse finding, warning letter,
untitled letter or other correspondence or notice from the U.S. Food and Drug Administration or any other governmental authority alleging or asserting noncompliance with any laws applicable to the Company, except where the failure to be in
compliance has not resulted and would not reasonably be expected to result in a Material Adverse Change. 

  
 Annex B-14.

 2.33 Compliance with Cuba Act. The Company has complied with, and is and will
be in compliance with, the provisions of that certain Florida act relating to disclosure of doing business with Cuba, codified as Section 517.075 of the Florida statutes, and the rules and regulations thereunder (collectively, the “Cuba
Act”) or is exempt therefrom. 
 2.34 Clinical Trials. The studies, tests and preclinical and clinical
trials conducted by or on behalf of the Company and its subsidiaries were and, if still pending, are being conducted in compliance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all
applicable laws and authorizations, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder, except where the failure to be in compliance has not resulted and would not reasonably
be expected to result in a Material Adverse Change; the descriptions of the results of such studies, tests and trials contained in the SEC Reports are accurate and complete in all material respects and fairly present the data derived from such
studies, tests and trials; the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the SEC Reports when viewed in
the context in which such results are described and the clinical state of development; and the Company and its subsidiaries have not received any notices or correspondence from any applicable governmental authority requiring the termination,
suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company or its subsidiaries. 
 2.35 Foreign Corrupt Practices Act. Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person
acting on behalf of the Company or any of its subsidiaries is aware of or has taken any action, directly or indirectly, that has resulted or would result in a violation of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and
regulations thereunder (the “FCPA”), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the
payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any
candidate for foreign political office, in contravention of the FCPA; and the Company and its subsidiaries and, to the knowledge of the Company, the Company’s affiliates have conducted their respective businesses in compliance with the FCPA and
have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. 
 2.36 Money Laundering Laws. The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting
requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or
guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money  

  
 Annex B-15.

 
Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries
with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. 
 2.37
OFAC. Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate or person acting on behalf of the Company or any of its subsidiaries is currently subject to
any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”); and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise
make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC. 

2.38 Rating Agencies. No “nationally recognized statistical rating organization” (as defined in Rule 436(g)(2)
under the Securities Act) (i) has imposed (or has informed the Company that it is considering imposing) any condition (financial or otherwise) to retain any rating assigned to the Company or any of the subsidiaries or to any securities of the
Company or any of the subsidiaries or (ii) has indicated to the Company that it is considering (A) the downgrading, suspension, or withdrawal of, or any review (or of any potential or intended review) for a possible change in, any rating
so assigned (including, without limitation, the placing of any of the foregoing ratings on credit watch with negative or developing implications or under review with an uncertain direction) or (B) any change in the outlook for any rating of the
Company or any of the subsidiaries or any securities of the Company or any of the subsidiaries. 
 2.39 This Agreement and
the Indenture. This Agreement has been duly and validly authorized, executed and delivered by the Company. The Indenture has been duly and validly authorized by the Company. This Agreement constitutes a valid and binding agreement of, the
Company, enforceable in accordance with its terms, except as rights to indemnification hereunder may be limited by applicable law and except as the enforcement hereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other
similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles. The Indenture, when executed and delivered by the Company, will constitute a legal, valid and binding obligation of each of the Company,
enforceable against the Company in accordance with its terms, except that the enforcement thereof may be subject to (i) bankruptcy, insolvency, reorganization, receivership, moratorium, fraudulent conveyance, fraudulent transfer or other
similar laws now or hereafter in effect relating to creditors’ rights generally and (ii) general principles of equity (whether applied by a court of law or equity) and the discretion of the court before which any proceeding therefor may be
brought. When executed and delivered, this Agreement and the Indenture will conform in all material respects to the descriptions thereof in the Placement Memorandum. When executed and delivered by the Company, the Indenture will meet the
requirements for qualification under the Trust Indenture Act of 1939, as amended, and the rules and regulations of the SEC thereunder (collectively, the “TIA”). 

2.40 Notes. The Notes have each been duly and validly authorized by the Company and, in the case of the Notes, when issued
and delivered to and paid for by the 

  
 Annex B-16.

 
Purchasers in accordance with the terms of this Agreement and the Indenture, will have been duly executed, authenticated, issued and delivered and will constitute legal, valid and binding
obligations of the Company, entitled to the benefit of the Indenture and enforceable against the Company in accordance with their terms, except that the enforcement thereof may be subject to (i) bankruptcy, insolvency, reorganization,
receivership, moratorium, fraudulent conveyance, fraudulent transfer or other similar laws now or hereafter in effect relating to creditors’ rights generally and (ii) general principles of equity (whether applied by a court of law or
equity) and the discretion of the court before which any proceeding therefor may be brought. When executed and delivered, the Notes will conform in all material respects to the descriptions thereof in the Placement Memorandum and will be in the form
contemplated by the Indenture. 
 2.41 Use of Proceeds; Solvency; Going Concern. All indebtedness represented by the
Notes is being incurred for proper purposes and in good faith. On the Closing Date, after giving pro forma effect to the Offering and the use of proceeds therefrom, the Company (i) will be Solvent (as hereinafter defined), (ii) will have
sufficient capital for carrying on its business and (iii) will be able to pay its debts as they mature. As used in this paragraph, the term “Solvent” means, with respect to a particular date, that on such date (i) the
present fair market value (or present fair saleable value) of the assets of the Company is not less than the total amount required to pay the liabilities of the Company on its total existing debts and liabilities (including contingent liabilities)
as they become absolute and matured; (ii) the Company is able to pay its debts and other liabilities, contingent obligations and commitments as they mature and become due in the normal course of business; (iii) assuming consummation of the
issuance of the Notes as contemplated by this Agreement and the Placement Memorandum, the Company is not incurring debts or liabilities beyond its ability to pay as such debts and liabilities mature; (iv) the Company is not engaged in any
business or transaction, and does not propose to engage in any business or transaction, for which its property would constitute unreasonably small capital after giving due consideration to the prevailing practice in the industry in which the Company
is engaged; and (v) the Company is not otherwise insolvent under the standards set forth in Applicable Laws. 
 2.42 No
Registration Required Under the Securities Act or Qualification Under the TIA. Without limiting any provision herein, no registration under the Securities Act and no qualification of the Indenture under the TIA is required for the offer or sale
of the Notes to the Purchaser as contemplated hereby, assuming (i) that the Purchaser is a “qualified institutional buyers” as defined in Rule 144A under the Securities Act or an “accredited investor” as defined in
Regulation D and (ii) the accuracy of the Purchaser’s representations contained herein regarding the absence of general solicitation in connection with the sale of the Notes to the Purchasers and in the Exempt Resales. 

2.43 No Integration. The Notes will be, upon issuance, eligible for resale pursuant to Rule 144A under the Securities Act
and no other securities of the Company are of the same class (within the meaning of Rule 144A under the Securities Act) as the Notes and listed on a national securities exchange registered under Section 6 of the Exchange Act, or quoted in a
U.S. automated inter-dealer quotation system. No securities of the Company of the same class as the Notes have been offered, issued or sold by the Company or any of its Affiliates within the six-month period immediately prior to the date hereof; and
the Company does not have any 

  
 Annex B-17.

 
intention of making, and will not make, an offer or sale of such securities of the Company of the same class as the Notes, for a period of six months after the date of this Agreement. As used in
this paragraph, the terms “offer” and “sale” have the meanings specified in Section 2(a)(3) of the Securities Act. 
 2.44 No Directed Selling Efforts. None of the Company, any of its Affiliates or other person acting on behalf of the Company has, with respect to Notes sold outside the United States, offered the
Notes to buyers qualifying as “U.S. persons” (as defined in Rule 902 under the Securities Act) or engaged in any directed selling efforts within the meaning of Rule 902 under the Securities Act; the Company, any Affiliate of the Company
and any person acting on behalf of the Company have complied with and will implement the “offering restrictions” within the meaning of such Rule 902; and neither the Company nor any of its Affiliates has entered or will enter into any
arrangement or agreement with respect to the distribution of the Notes, except for this Agreement; provided that no representation is made in this paragraph with respect to the actions of the Purchaser. 

2.45 Margin Requirements. None of the transactions contemplated by this Agreement or the Placement Memorandum or the application
of the proceeds of the Notes will violate or result in a violation of Section 7 of the Exchange Act (including, without limitation, Regulation T (12 C.F.R. Part 220), Regulation U (12 C.F.R. Part 221) or Regulation X (12 C.F.R. Part 224) of the
Board of Governors of the Federal Reserve System). 
 2.46 No Restrictions on Payments of Dividends. As of the Closing
Date, except as otherwise disclosed in the SEC Reports there will be no encumbrances or restrictions on the ability of any Subsidiary of the Company (x) to pay dividends or make other distributions on such Subsidiary’s capital stock or to
pay any indebtedness to the Company or any other Subsidiary of the Company, (y) to make loans or advances or pay any indebtedness to, or investments in, the Company or any other Subsidiary or (z) to transfer any of its property or assets
to the Company or any other Subsidiary of the Company. 
 2.47 Stamp Taxes. There are no stamp or other issuance
or transfer taxes or duties or other similar fees or charges required to be paid in connection with the execution and delivery of this Agreement or the issuance or sale of the Notes; provided however, if any of the Notes are executed or
delivered in Florida (each a “Florida Note”), Florida documentary stamp for each Florida Note will be due and payable. 
 2.48 Financial Services and Market Act. The Company has not taken or omitted to take any action and will not take any action or omit to take any action (such as issuing any press release or
making any other public announcement referring to the Offering without an appropriate stabilization legend) which may result in the loss by the Initial Purchaser of the ability to rely on any stabilization safe harbour provided by the Financial
Services Authority of the United Kingdom under the Financial Services and Markets Act 2000 (the “FSMA”); provided, however, that an appropriate stabilization legend was not in the Preliminary Offering Memorandum or the
Pricing Term Sheet. The Company has been informed of the guidance relating to stabilization provided by the Financial Services Authority of the United Kingdom, in particular the guidance contained in Section MAR 2 of the Financial Services Handbook.

  
 Annex B-18.

 2.49 Certificates. Each certificate signed by any officer of the Company or any of
the Subsidiaries, delivered to the Purchaser shall be deemed a representation and warranty by the Company or any such Subsidiary (and not individually by such officer) to the Purchaser with respect to the matters covered thereby. 

2.50 Acknowledgement. The Company acknowledges that the Purchasers and, for purposes of the opinions to be delivered
pursuant to Section 1.5(b) hereof, counsel to the Company, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance. 

2.51 Offering Materials. The Company has not in the past nor will it hereafter take any action independent of Jefferies, in such
capacities as placement agent and closing agent, to sell, offer for sale or solicit offers to buy any securities of the Company that could result in the initial sale of the Notes not being exempt from the registration requirements of Section 5
of the Securities Act. 
 2.52 Non-Public Information. The Company has not disclosed to the Purchaser information that
would constitute material non-public information as of the Closing Date other than the existence of the transactions contemplated hereby. 
 2.53 Use of Purchaser Name. Except as otherwise required by applicable law or regulation, the Company shall not use the Purchaser’s name or the name of any of its Affiliates (as defined below)
in any advertisement, announcement, press release or other similar public communication unless it has received the prior written consent of the Purchaser for the specific use contemplated, which consent shall not be unreasonably withheld or delayed.
For purposes of this Agreement, “Affiliate” means, with respect to any natural person, firm, partnership, association, corporation, limited liability company, company, trust, entity, public body or government (a
“Person”), any Person that, directly or indirectly, controls, is controlled by, or is under common control with, such Person. The term “control” (including the terms “controlled by” and “under common control
with”) as used in this definition means the possession, directly or indirectly, of the power to direct or cause the direction of management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.
With respect to any natural person, the term “Affiliate” means (i) the spouse or children (including those by adoption) and siblings of such Person; and any trust whose primary beneficiary is such Person, such Person’s
spouse, such Person’s siblings and/or one or more of such Person’s lineal descendants, (ii) the legal representative or guardian of such Person or of any such immediate family member in the event such Person or any such immediate
family member becomes mentally incompetent and (iii) any Person controlled by or under common control with any one or more of such Person and the Persons described in clauses (i) or (ii) preceding. 

2.54 Integration; Other Issuances of Securities. The Company has not issued any Notes, shares of Common Stock or other securities
or instruments convertible into, exchangeable for or otherwise entitling the holder thereof to acquire shares of Common Stock that would be integrated with the sale of the Notes to the Purchaser for purposes of the Securities Act or that would
require or violate any applicable stockholder approval provisions, including, without limitation, under the rules and regulations of the NYSE. Assuming the accuracy of the 

  
 Annex B-19.

 
representations and warranties of the Purchasers to the Company as set forth herein, the offer and sale of the Notes and the issuance of the Conversion Shares by the Company to the Purchasers
pursuant to the Agreements (i) will be exempt from the registration requirements of the Securities Act and (ii) will not require the Indenture to be qualified under the Trust Indenture Act of 1939, as amended. 

3. Representations, Warranties and Covenants of the Purchaser. The Purchaser represents and warrants to, and covenants with, the
Company that: 
 3.1 Experience. (i) The Purchaser is knowledgeable, sophisticated and experienced in financial and
business matters, in making, and is qualified to make, decisions with respect to investments in shares representing an investment decision like that involved in the purchase of the Notes (and the Conversion Shares into which the Notes are
convertible), and the Purchaser has undertaken an independent analysis of the merits and the risks of an investment in the Notes (and the Conversion Shares into which the Notes are convertible) and has reviewed carefully the SEC Reports, based on
the Purchaser’s own financial circumstances; (ii) the Purchaser understands that its investment in the Notes (and the Conversion Shares into which the Notes are convertible) involves a significant degree of risk, including a risk of total
loss of the Purchaser’s investment, and the Purchaser understands that the market price of the Common Stock into which such Notes are convertible has been volatile and that no representation is being made as to the future value of the Common
Stock; (iii) the Purchaser has had the opportunity to request, receive, review and consider all information it deems relevant in making an informed decision to purchase the Notes (and the Conversion Shares into which the Notes are convertible)
and to ask questions of, and receive answers from, the Company concerning such information; (iv) the Purchaser will comply with the prospectus delivery requirements of the Securities Act as applicable to it in connection with resales of the
Conversion Shares pursuant to any exemption from the Securities Act; and (v) the Purchaser has, in connection with its decision to purchase the principal amount of Notes set forth on the signature page to the Agreement, relied solely upon the
SEC Reports and the representations and warranties of the Company contained herein, and the Purchaser has not relied on Jefferies and Ladenburg in negotiating the terms of its investment in the Notes (and the Conversion Shares into which the Notes
are convertible) and, in making a decision to purchase the Notes (and the Conversion Shares into which the Notes are convertible), the Purchaser has not received or relied on any communication, investment advice or recommendation from Jefferies or
Ladenburg. 
 3.2 Purchaser Status. Each of the Purchasers acknowledges that (i) it is an “accredited
investor” as defined in Rule 501(a)(1), (2), (3), (4), (5), (6), (7) or (8) of Regulation D under the Securities Act and/or it meets the definition of “qualified institutional buyers” as defined in Rule 144A(a)(1) under the
Securities Act and (ii) is not an entity formed for the sole purpose of acquiring the Securities. 
 3.3 Intent. The
Purchaser is acquiring the principal amount of Notes set forth on the signature page to the Agreement in the ordinary course of its business and for its own account and with no present intention of distributing any of such Notes or the Conversion
Shares or any arrangement or understanding with any other Persons regarding the distribution of such Notes or Conversion Shares. 

  
 Annex B-20.

 3.4 Source of Funds. Each Purchaser of the Notes will be deemed to have represented
and agreed as follows: (i) either: (A) the Purchaser is not a Plan (which term includes (i) “employee benefit plans” (as defined in Section 3(3) of ERISA, (ii) plans, individual retirement accounts and other
arrangements that are subject to Section 4975 of the Code, or to provisions under applicable Federal, state, local. non-U.S. or similar laws and (iii) entities the underlying assets of which are considered to include “plan
assets” of such plans, accounts and arrangements) and it is not purchasing the Notes on behalf of, or with the “plan assets” of, any Plan; or (B) the Purchaser’s purchase, holding and subsequent disposition of the Notes
either (i) are not a prohibited transaction under ERISA or the Code and are otherwise permissible under all applicable similar laws or (ii) are entitled to exemptive relief from the prohibited transaction provisions of ERISA and the Code
in accordance with one or more available statutory. class or individual prohibited transaction exemptions and are otherwise permissible under all applicable similar laws. 
 3.5 Reliance on Exemptions. The Purchaser understands that the Notes (and the Conversion Shares into which the Notes are convertible) are being offered and sold to it in reliance upon specific
exemptions from the registration requirements of the Securities Act, the Rules and Regulations and state securities laws and that the Company is relying upon the truth and accuracy of, and the Purchaser’s compliance with, the representations,
warranties, agreements, acknowledgments and understandings of the Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of the Purchaser to acquire the Notes (and the Conversion Shares into which
the Notes are convertible). 
 3.6 Confidentiality. For the benefit of the Company, the Purchaser previously agreed to
keep confidential all information concerning this private placement. The Purchaser is prohibited from reproducing or distributing this Agreement or any other offering materials or other information provided by the Company in connection with the
Purchaser’s consideration of its investment in the Company, in whole or in part, or divulging or discussing any of their contents, except to its financial, investment or legal advisors in connection with its proposed investment in the Notes
(and the Conversion Shares into which the Notes are convertible) or as required by applicable law or regulation. Further, the Purchaser understands that the existence and nature of all conversations and presentations, if any, regarding the Company
and this offering must be kept strictly confidential. The Purchaser understands that the federal securities laws impose restrictions on trading based on information regarding this offering. In addition, the Purchaser hereby acknowledges that
unauthorized disclosure of information regarding this offering may result in a violation of Regulation FD. This obligation will terminate upon the filing by the Company of the Press Release (as defined below), which shall include any material,
non-public information provided to the Purchaser prior to the date hereof. The foregoing agreements shall not apply to any information that is or becomes publicly available through no fault of the Purchaser, or that the Purchaser is legally required
to disclose; provided, however, that if the Purchaser is requested or ordered to disclose any such information pursuant to any court or other government order or any other applicable legal procedure, it shall use its reasonable best
efforts to provide the Company with prompt notice of any such request or order in time sufficient to enable the Company to seek an appropriate protective order. 

  
 Annex B-21.

 3.7 Investment Decision. The Purchaser understands that nothing in the Agreement or
any other materials presented to the Purchaser in connection with the purchase and sale of the Notes (and the Conversion Shares into which the Notes are convertible) constitutes legal, tax or investment advice. The Purchaser has consulted such
legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Notes (and the Conversion Shares into which the Notes are convertible). 

3.8 Legend. The Purchaser understands that the Notes and the Conversion Shares will bear a restrictive legend as set forth in the
Indenture. 
 3.9 Residency. The Purchaser’s principal executive offices are in the jurisdiction set forth
immediately below the Purchaser’s name on the signature page hereto. 
 3.10 Organization; Validity; Enforcements.
(i) The Purchaser has full right, power and authority to enter into this Agreement and to consummate the transactions contemplated hereby and has taken all necessary action to authorize the execution, delivery and performance of this Agreement,
(ii) the making and performance of this Agreement by the Purchaser and the consummation of the transactions herein contemplated will not violate any provision of the organizational documents of the Purchaser or conflict with, result in the
breach or violation of, or constitute, either by itself or upon notice or the passage of time or both, a default under any material agreement, mortgage, deed of trust, lease, franchise, license, indenture, permit or other instrument to which the
Purchaser is a party or, any statute or any authorization, judgment, decree, order, rule or regulation of any court or any regulatory body, administrative agency or other governmental agency or body applicable to the Purchaser, (iii) no
consent, approval, authorization or other order of any court, regulatory body, administrative agency or other governmental agency or body is required on the part of the Purchaser for the execution and delivery of this Agreement or the consummation
of the transactions contemplated by this Agreement, (iv) upon the execution and delivery of this Agreement, this Agreement shall constitute a legal, valid and binding obligation of the Purchaser, enforceable in accordance with its terms, except
as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws or judicial decisions of general application relating to or affecting the enforcement of creditors’ rights generally
and the application of equitable principles relating to the availability of remedies, and except as rights to indemnity or contribution may be limited by federal or state securities laws or the public policy underlying such laws and (v) there
is not in effect any order enjoining or restraining the Purchaser from entering into or engaging in any of the transactions contemplated by this Agreement. 
 4. Covenants. The Company shall: 
 (a) file a Form D with the Commission
with respect to the Notes as required under Regulation D promulgated under the Securities Act and to provide a copy thereof to the Purchaser promptly after filing; 
 (b) issue a press release describing the transactions contemplated by this Agreement (the “Press Release”) on or before 9:00 a.m., New York City time, on the first business day following
the date hereof; 

  
 Annex B-22.

 (c) not, and shall cause each of its Subsidiaries and each of their respective officers,
directors, employees and agents not to, provide any Purchaser with any material, non-public information regarding the Company or any of its Subsidiaries from and after the filing of the Press Release without the express written consent of such
Purchaser; 
 (d) in order to enable the Purchasers to sell the Conversion Shares under Rule 144 under the Securities Act, for
a period of one year from Closing, use its reasonable best efforts to comply with the requirements of Rule 144, including without limitation, use its reasonable best efforts to comply with the requirements of Rule 144(c) with respect to public
information about the Company and to timely file all reports required to be filed by the Company under the Exchange Act; 
 (e)
during the period commencing on the date hereof and ending on the 90th day following the date hereof (the “Lock-up Period”), without the prior written consent of Jefferies, not directly or indirectly, sell, offer, contract or grant
any option to sell, pledge, transfer or establish an open “put equivalent position” within the meaning of Rule 16a-l(h) under the Exchange Act, or otherwise dispose of or transfer, or announce the offering of, or file any registration
statement under the Securities Act in respect of, any shares of Common Stock, options or warrants to acquire shares of Common Stock or securities exchangeable or exercisable for or convertible into shares of Common Stock (other than as contemplated
with respect to the conversion of the Notes into the Conversion Shares); provided, however, that the Company may (i) issue shares of its Common Stock, options to purchase its shares of Common Stock or shares of Common Stock upon
exercise of options, pursuant to any stock option, stock bonus or other stock plan or arrangement approved by the Board of Directors of the Company and as disclosed in the SEC Reports, (ii) issue shares of Common Stock pursuant to that certain
acquisition agreement, dated December 26, 2012, in connection with the Company’s proposed acquisition of Silcon Comercio, (iii) issue shares of Common Stock pursuant to that certain share purchase agreement, dated January 8,
2013, in connection with the Company’s proposed acquisition of Cytochroma Inc. (Markham Canada), and (iv) the sale or issuance of or entry into an agreement to sell or issue shares of Common Stock in connection with the Company’s
acquisition of one or more businesses, products or technologies (whether by means of merger, stock purchase, asset purchase or otherwise) or in connection with joint ventures, commercial relationships or other strategic transactions;
provided, that, the aggregate number of unregistered shares of Common Stock that the Company may sell or issue or agree to sell or issue pursuant to this clause (iv) shall not exceed 5% of the total number of shares of Common Stock
issued and outstanding on the date hereof; provided further, that that shares of Common Stock to be issued pursuant to clauses (ii), (iii) and (iv) shall not be registered pursuant to the Securities Act. 

(f) on or prior to the date hereof, have furnished to the Purchasers an agreement in the form of Annex F hereto from each
director and executive officer of the Company that is subject to the reporting requirements under Section 16 of the Securities Act, and such agreement shall be in full force and effect on the Closing Date; 

(g) maintain, at its expense, a registrar and transfer agent for the shares of Common Stock (including the Conversion Shares); and

  
 Annex B-23.

 (h) cause the Common Stock to remain listed on the NYSE or other applicable U.S. national
securities exchange upon which shares of Common Stock are then listed. 
 5. Broker’s Fee. The Purchaser
acknowledges that the Company intends to pay to Jefferies and Ladenburg a fee in respect of the sale of the Notes to the Purchaser. The Purchaser and the Company agree that the Purchaser shall not be responsible for such fee and that the Company
will indemnify and hold harmless the Purchaser against any losses, claims, damages, liabilities or expenses, joint or several, to which such Purchaser may become subject with respect to such fee. Each of the parties hereto represents that, on the
basis of any actions and agreements by it, there are no other brokers or finders entitled to compensation in connection with the sale of the Notes to the Purchaser. 
 6. Independent Nature of Purchasers’ Obligations and Rights. The obligations of the Purchaser under this Agreement are several and not joint with the obligations of any Other Purchaser, and no
Purchaser shall be responsible in any way for the performance of the obligations of any Other Purchaser under the Agreements. The decision of each Purchaser to purchase the Notes (and the Conversion Shares into which the Notes are convertible)
pursuant to the Agreements has been made by such Purchaser independently of any other Purchaser. Nothing contained in the Agreements, and no action taken by any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as a
partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Agreements.
Each Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser in connection with making its investment hereunder and that no Purchaser will be acting as agent of such Purchaser in connection with monitoring its investment
in the Notes (and the Conversion Shares into which the Notes are convertible) or enforcing its rights under this Agreement. Each Purchaser shall be entitled to independently protect and enforce its rights, including without limitation the rights
arising out of this Agreement, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. 
 7. Notices. All notices, requests, consents and other communications hereunder shall be in writing, shall be mailed by first-class registered or certified airmail, e-mail, confirmed facsimile or
nationally recognized overnight express courier postage prepaid, and shall be deemed given when so mailed and shall be delivered as addressed as follows: 
 if to the Company, to: 
 OPKO Health, Inc. 

4400 Biscayne Blvd. 
 Miami, Florida 33137 
 Attention: Kate Inman, Deputy General Counsel 

E-mail: kinman@opko.com 
 Facsimile: (305) 575-4140 

  
 Annex B-24.

 with a copy to: 
 Akerman Senterfitt 
 One Southeast Third Avenue 

25th Floor 
 Miami, Florida 33131 
 Teddy D. Klinghoffer, Esq. 

E-mail: teddy.klinghoffer@akerman.com 
 Attention: Esther L. Moreno, Esq. 
 E-mail:
esther.moreno@akerman.com 
 Facsimile: (305) 374-5095 

or to such other person at such other place as the Company shall designate to the Purchaser in writing; and 

if to the Purchaser, at its address as set forth on this signature page to this Agreement, or at such other address or
addresses as may have been furnished to the Company in writing. 
 8. Changes. This Agreement may not be modified or
amended except pursuant to an instrument in writing signed by the Company and the Purchaser. Any amendment or waiver effected in accordance with this Section 7 shall be binding upon each holder of any securities purchased under this
Agreement at the time outstanding, each future holder of all such securities, and the Company. 
 9. Survival of Agreements;
Non-Survival of Company Representations and Warranties. Notwithstanding any investigation made by any party to this Agreement or by Jefferies or Ladenburg, all covenants and agreements made by the Company and the Purchaser herein and in the
Notes delivered pursuant hereto shall survive the execution of this Agreement, the delivery to the Purchaser of the Notes being purchased and the payment therefor. All representations and warranties made by the Company and the Purchaser herein and
in the Notes delivered pursuant hereto shall survive for a period of two years following the later of the date of execution of this Agreement or the date of delivery to the Purchaser of the Notes being purchased upon payment therefor. 

10. Headings. The headings of the various sections of this Agreement have been inserted for convenience of reference only and
shall not be deemed to be part of this Agreement. 
 11. Severability. In case any provision contained in this Agreement
should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. 

12. Governing Law; Venue. This Agreement is to be construed in accordance with the internal laws of the State of New York. Each
party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees 

  
 Annex B-25.

 
not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an
inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy
thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way
any right to serve process in any manner permitted by law. Each party hereby irrevocably waives any right it may have, and agrees not to request, a jury trial for the adjudication of any dispute hereunder or in connection with or arising out of this
Agreement or any transaction contemplated hereby. If either party shall commence a proceeding to enforce any provisions of this Agreement, then the prevailing party in such proceeding shall be reimbursed by the other party for its attorney’s
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such proceeding. 
 13.
Counterparts. This Agreement may be executed in counterparts, each of which shall constitute an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts
have been signed by each party hereto and delivered to the other parties. Delivery of an executed counterpart of this Agreement by facsimile transmission or electronic mail in PDF form shall be as effective as delivery of a manually executed
counterpart hereof. 
 14. Entire Agreement. This Agreement and the instruments referenced herein contain the entire
understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Purchaser makes any representation, warranty, covenant or undertaking with
respect to such matters. Each party expressly represents and warrants that it is not relying on any oral or written representations, warranties, covenants or agreements outside of this Agreement. 

15. Fees and Expenses. Except as set forth herein, each of the Company and the Purchaser shall pay its respective fees and
expenses related to the transactions contemplated by this Agreement. 
 16. Parties. This Agreement is made solely for
the benefit of and is binding upon the Purchaser and the Company and to the extent provided in Section 18, any Person controlling the Company or the Purchaser, the officers and directors of the Company, and their respective executors,
administrators, successors and assigns, no other Person shall acquire or have any right under or by virtue of this Agreement except that Jefferies and Ladenburg are intended third-party beneficiary of this Agreement as set forth in
Section 18. The term “successor and assigns” shall not include any subsequent purchaser, as such purchaser, of the Notes or of any Conversion Shares issued to such Purchaser upon the conversion of the Notes sold to the
Purchaser pursuant to this Agreement. 

  
 Annex B-26.

 17. Further Assurances. Each party agrees to cooperate fully with the other parties
and to execute such further instruments, documents and agreements and to give such further written assurance as may be reasonably requested by any other party to evidence and reflect the transactions described herein and contemplated hereby and to
carry into effect the intents and purposes of this Agreement. 
 18. Reliance by and Exculpation of Jefferies as Closing
Agent and Placement Agent and Ladenburg as Placement Agent. The Purchaser acknowledges that (i) Jefferies and Ladenburg have not made, and will not make any representations and warranties with respect to the Company or the offer and sale of
the Notes, and the Purchaser will not rely on any statements made by Jefferies or Ladenburg, orally or in writing, to the contrary; (ii) it will be responsible for conducting its own due diligence investigation with respect to the Company and
the offer and sale of the Notes, (iii) it will be purchasing Notes based on the results of its own due diligence investigation of the Company, (iv) it has negotiated the offer and sale of the Notes directly with the Company, and Jefferies
and Ladenburg will not be responsible for the ultimate success of any such investment and (v) the decision to invest in the Company will involve a significant degree of risk, including a risk of total loss of such investment. The Purchaser
further represents and warrants to Jefferies and Ladenburg that it, including any fund or funds that it manages or advises that participates in the offer and sale of the Notes, is permitted under its constitutive documents (including, without
limitation, all limited partnership agreements, charters, bylaws, limited liability company agreements, all applicable side letters with investors, and similar documents) to make investments of the type contemplated by this Agreement. In light of
the foregoing, to the fullest extent permitted by law, the Purchaser and the Company release each of Jefferies and Ladenburg, their employees, officers and affiliates from any liability with respect to the Purchaser’s participation in the offer
and sale of the Notes including, but not limited to, any improper payment made in accordance with the information provided by the Company. This Section 18 shall survive any termination of this Agreement. Jefferies and Ladenburg have
introduced the Purchaser to the Company in reliance on the Purchaser’s understanding and agreement to this Section 18. 
 The parties agree and acknowledge that Jefferies and Ladenburg may rely on the representations, warranties, agreements and covenants of the Company contained in this Agreement and may rely on the
representations and warranties of the respective Purchasers contained in this Agreement as if such representations, warranties, agreements, and covenants, as applicable, were made directly to Jefferies and Ladenburg. The parties further agree that
Jefferies and Ladenburg may rely on the legal opinions to be delivered pursuant to Section 1.5(b) hereof. 
 Each
party hereto agrees for the express benefit of Jefferies, as Closing Agent and a placement agent, and Ladenburg as a placement agent, that: (1) neither Jefferies nor Ladenburg, nor any of their affiliates or any of their representatives
(A) shall be liable for any improper payment made in accordance with the information provided by the Company; (B) makes any representation or warranty, or has any responsibilities as to the validity, accuracy, value or genuineness of any
information, certificates or documentation delivered by or on behalf of the Company pursuant to this Agreement; or (C) shall be liable (x) for any action taken, suffered or omitted by any of them in good faith and reasonably believed to be
authorized or within the 

  
 Annex B-27.

 
discretion or rights or powers conferred upon it by this Agreement or (y) for anything which any of them may do or refrain from doing in connection with this Agreement, except for such
party’s own gross negligence, willful misconduct or bad faith; and (2) Jefferies and Ladenburg, their affiliates and their representatives shall be entitled to (A) rely on, and shall be protected in acting upon, any certificate,
instrument, opinion, notice, letter or any other document or security delivered to any of them by or on behalf of the Company, and (B) be indemnified by the Company for acting as placement agents and Closing Agent, respectively, hereunder.

 [Remainder of Page Left Intentionally Blank] 

  
 Annex B-28.

 ANNEX C 
 REGISTRATION RIGHTS 
 TERMS AND CONDITIONS 

1. Definitions. As used in this Annex C to this Agreement, the following terms shall have the following meanings:

 “Additional Filing Deadline” has the meaning set forth in Section 2(f)(v) hereof. 

“Additional Interest” has the meaning set forth in Section 2(f) hereof. 

“Affiliate” means with respect to any specified person, an “affiliate,” as defined in Rule 144, of such
person. 
 “Amendment Effectiveness Deadline” has the meaning set forth in Section 2(e)(i) hereof.

 “Annex C” means this Annex C, “Registration Rights Terms and Conditions.” 

“Business Day” means any day, except a Saturday, Sunday or legal holiday on which banking institutions in The City of
New York are authorized or obligated by law or executive order to close. 
 “Common Stock” means the shares of
common stock, par value $0.01 per share, of the Company, and any other shares of common stock as may constitute “Common Stock” for purposes of the Indenture, including the Underlying Common Stock. 

“Deferral Notice” has the meaning set forth in Section 3(h)(ii) hereof. 

“Deferral Period” has the meaning set forth in Section 3(h)(ii) hereof. 

“Effective Date” means, with respect to a Shelf Registration Statement, the first date that such Shelf Registration
Statement is declared effective. 
 “Effectiveness Deadline” has the meaning set forth in Section 2(a)
hereof. 
 “Effectiveness Period” means the period commencing on the Effective Date and ending on the earliest
to occur of (1) the date all of the Registrable Securities have been sold pursuant to the Shelf Registration Statement, (2) the two-year anniversary of the Effective Date, subject to extension in the event of a suspension of the use of the
Prospectus as described herein and (3) the date no Registrable Securities remain outstanding. 
 “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the SEC promulgated thereunder. 
 “Filing Deadline” has the meaning set forth in Section 2(a) hereof. 
 “FINRA” means the Financial Industry Regulatory Authority, Inc. 

  
 Annex C

 “Free Writing Prospectus” has the meaning set forth in Rule 405.

 “Fundamental Change Repurchase Date” has the meaning set forth in the Indenture. 

“Holders” means the beneficial owners from time to time of the Securities and the Underlying Common Stock (as defined
herein) issued upon conversion of the Securities. 
 “indemnified party” has the meaning set forth in
Section 6(c). 
 “indemnifying party” has the meaning set forth in Section 6(c). 

“Indenture” means the Indenture to be dated as of the Closing Date between the Company and the Trustee, pursuant to
which the Securities are being issued. 
 “Interest Payment Date” means each February 1 and August 1
of each year. 
 “Issue Date” means the last date of original issuance of the Securities. 

“Issuer Free Writing Prospectus” has the meaning set forth in Rule 433. 

“Material Event” has the meaning set forth in Section 3(h) hereof. 

“Notice and Questionnaire” means a written notice delivered to the Company containing substantially the information
called for by the Selling Securityholder Notice and Questionnaire attached as Annex A to the Private Placement Memorandum of the Company, collectively dated as of January 23, 2013 and January 25, 2013, relating to the
Securities. 
 “Notice Holder” means, on any date, any Holder that has delivered a Notice and Questionnaire to
the Company on or prior to such date. 
 “Purchase Agreement” means the Note Purchase Agreement of which this
Annex C is a part. 
 “Prospectus” means a prospectus relating to a Shelf Registration Statement, as
amended or supplemented, and all materials incorporated by reference in such Prospectus. 
 “Record Date” means
each January 15 and July 15 of each year. 
 “Record Holder” means with respect to any Interest
Payment Date relating to any Securities as to which any Additional Interest has accrued, the registered holder of such Security on the Record Date immediately preceding the Interest Payment Date. 

“Redemption Date” has the meaning set forth in the Indenture. 

“Registrable Securities” means the Securities, the Underlying Common Stock and any securities into or for which such
Underlying Common Stock has been converted or exchanged, and any security issued with respect thereto upon any stock dividend, split or similar event until, in the case of any such security, the earlier of (i) its effective registration under
the Securities Act and resale in accordance with a Shelf Registration Statement or (ii) resale to the public pursuant to Rule 144. 

  
 Annex C-2.

 “Registration Default” has the meaning set forth in Section 2(f)
hereof. 
 “Registration Default Period” has the meaning set forth in Section 2(f) hereof. 

“Rule 144” means Rule 144 under the Securities Act, as such Rule may be amended from time to time, or any similar rule
or regulation hereafter adopted by the SEC. 
 “Rule 144A” means Rule 144A under the Securities Act, as such
Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC. 
 “Rule
405” means Rule 405 under the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC. 
 “Rule 424” means Rule 424 under the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC. 

“Rule 430B” means Rule 430B under the Securities Act, as such Rule may be amended from time to time, or any similar rule
or regulation hereafter adopted by the SEC. 
 “Rule 433” means Rule 433 under the Securities Act, as such Rule
may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC. 
 “Scheduled Trading
Day” has the meaning set forth in the Indenture. 
 “SEC” means the Securities and Exchange
Commission. 
 “Securities” means the 3.00% Convertible Senior Notes due 2033 of the Company to be purchased
pursuant to the Purchase Agreement. 
 “Securities Act” means the Securities Act of 1933, as amended, and the
rules and regulations promulgated by the SEC thereunder. 
 “Secondary Effectiveness Deadline” has the meaning
set forth in Section 2(a) hereof. 
 “Shelf Registration Statement” has the meaning set forth in
Section 2(a) hereof, including amendments to such registration statement, all exhibits to such registration statement and all materials incorporated by reference in such registration statement. 

“Special Counsel” means Cooley LLP or one such other successor counsel as shall be specified by the Holders of a
majority of the Registrable Securities. For purposes of determining Holders of a majority of the Registrable Securities in this definition, Holders of Securities shall be deemed to be the Holders of the number of shares of Underlying Common Stock
into which such Securities have been or would be convertible as of the date the consent is requested. 
 “Stated
Maturity” has the meaning set forth in the Indenture. 

  
 Annex C-3.

 “Trustee” means Wells Fargo Bank, National Association, the Trustee under
the Indenture. 
 “Underlying Common Stock” means the Common Stock into which the Securities are convertible or
issued upon any such conversion. 
 2. Shelf Registration. (a) The Company shall prepare and file or cause to
be prepared and filed with the SEC, as soon as practicable but in any event within 135 days of the Issue Date (the “Filing Deadline”), a registration statement for an offering to be made on a delayed or continuous basis pursuant to
Rule 415 of the Securities Act registering the resale from time to time by Holders of the Registrable Securities (a “Shelf Registration Statement”). The Shelf Registration Statement shall be on Form S-3 or another appropriate form
permitting registration of the Registrable Securities for resale by the Holders in accordance with the methods of distribution elected by the Holders and set forth in the Shelf Registration Statement. If the Company is eligible pursuant to Rule
430B(b) to omit from the related Prospectus the identities of selling securityholders and the amounts of securities to be registered on their behalf, the Company shall prepare and file each Shelf Registration Statement in a manner as to permit such
omission and to allow for the subsequent filing of such information in a Prospectus pursuant to Rule 424(b) in the manner contemplated by Rule 430B(d). The Company shall use its commercially reasonable efforts to cause a Shelf Registration Statement
to be declared effective under the Securities Act as promptly as is practicable but in any event by the date (the “Effectiveness Deadline”) that is 270 days after the Issue Date, and to keep a Shelf Registration Statement
continuously effective under the Securities Act until the expiration of the Effectiveness Period. Each Holder that became a Notice Holder on or prior to the date five Business Days prior to the date the initial Shelf Registration Statement is
declared effective shall be named as a selling securityholder in the initial Shelf Registration Statement and the related Prospectus in such a manner as to permit such Holder to deliver the Prospectus to purchasers of Registrable Securities in
accordance with applicable law. None of the Company’s security holders shall have the right to include any of the Company’s securities in a Shelf Registration Statement, other than the Holders. In addition, the Company shall prepare and
file or cause to be prepared and filed with the SEC a Shelf Registration Statement that satisfies the foregoing requirements and use its commercially reasonable efforts to cause a Shelf Registration Statement to be declared effective under the
Securities Act prior to a Notice of Optional Redemption (as defined in the Indenture) (to the extent that a Shelf Registration Statement covering resales of the Registrable Securities is not then effective) (“Secondary Effectiveness
Deadline”). 
 (b) If a Shelf Registration Statement covering resales of the Registrable Securities ceases to be
effective for any reason at any time during the Effectiveness Period (other than because all securities registered thereunder shall have been resold pursuant thereto or shall have otherwise ceased to be Registrable Securities), the Company shall use
its commercially reasonable efforts to obtain the prompt withdrawal of any order suspending the effectiveness thereof, and in any event shall within 30 days of such cessation of effectiveness amend the Shelf Registration Statement in a manner
reasonably expected to obtain the withdrawal of the order suspending the effectiveness thereof, or file an additional Shelf Registration Statement so that all Registrable Securities outstanding as of the date of such filing are covered by a Shelf
Registration Statement. If a new Shelf Registration Statement is filed, the 

  
 Annex C-4.

 
Company shall use its commercially reasonable efforts to cause the new Shelf Registration Statement to become effective as promptly as is practicable after such filing and to keep the new Shelf
Registration Statement continuously effective until the end of the Effectiveness Period. 
 (c) The Company shall amend and
supplement the Prospectus and amend the Shelf Registration Statement if required by the rules, regulations or instructions applicable to the registration form used by the Company for such Shelf Registration Statement or file a new Shelf Registration
Statement, if required by the Securities Act, or any other documents necessary to name a Notice Holder as a selling securityholder pursuant to Section 2(e) below. 
 (d) The Company agrees that, unless it obtains the prior consent of the Holders of a majority of the Registrable Securities that are registered under the Shelf Registration Statement at such time or the
consent of the managing underwriters in connection with any underwritten offering of Registrable Securities, and each Holder agrees that, unless it obtains the prior written consent of the Company and any such underwriters, it will not make any
offer relating to the Securities that would constitute an Issuer Free Writing Prospectus, or that would otherwise constitute a Free Writing Prospectus required to be filed with the SEC. The Company represents that any Issuer Free Writing Prospectus
prepared by it or authorized by it in writing for use by such Holder will not include any information that conflicts with the information contained in the Shelf Registration Statement or the Prospectus and, any such Issuer Free Writing Prospectus,
when taken together with the information in the Shelf Registration Statement and the Prospectus, will not include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in light
of the circumstances under which they were made, not misleading. 
 (e) Each Holder may sell Registrable Securities pursuant to
a Shelf Registration Statement and related Prospectus only in accordance with this Section 2(e) and Section 3(h). Each Holder wishing to sell Registrable Securities pursuant to a Shelf Registration Statement and related Prospectus shall
deliver a Notice and Questionnaire to the Company prior to any intended distribution of Registrable Securities under the Shelf Registration Statement. From and after the date the initial Shelf Registration Statement is declared effective, the
Company shall, as promptly as practicable after the date a fully completed Notice and Questionnaire is delivered, and in any event no later than the later of (x) 15 calendar days after such date or (y) 15 calendar days after the
expiration of any Deferral Period in effect when the Notice and Questionnaire is delivered or put into effect within 5 Business Days of such delivery date: 
 (i) if required by applicable law, file with the SEC a post-effective amendment to the Shelf Registration Statement or prepare and, if required by applicable law, file a supplement to the related
Prospectus or a supplement or amendment to any document incorporated therein by reference or file a new Shelf Registration Statement or any other required document so that the Holder delivering such Notice and Questionnaire is named as a selling
securityholder in a Shelf Registration Statement and the related Prospectus in such a manner as to permit such Holder to deliver such Prospectus to purchasers of the Registrable Securities in accordance with applicable law and, if the Company shall
file a post-effective amendment to a Shelf Registration Statement or shall file a new Shelf Registration Statement, the Company shall use its commercially reasonable efforts to cause such post-effective amendment or new Shelf

  
 Annex C-5.

 
Registration Statement to be declared effective under the Securities Act as promptly as is practicable, but in any event by the date (the “Amendment Effectiveness Deadline”) that
is 45 days after the date such post-effective amendment or new Shelf Registration Statement is required by this clause to be filed; 
 (ii) provide such Holder, upon request and without charge, copies of any documents filed pursuant to Section 2(e)(i); and 
 (iii) notify Special Counsel as promptly as practicable after the effectiveness under the Securities Act of any new Shelf Registration Statement or post-effective amendment filed pursuant to
Section 2(e)(i); 
 provided that if such Notice and Questionnaire is delivered during a Deferral Period, the Company shall so
inform the Holder delivering such Notice and Questionnaire and shall take the actions set forth in clauses (i), (ii) and (iii) above upon expiration of the Deferral Period in accordance with Section 3(h). Notwithstanding anything
contained herein to the contrary, the Company shall be under no obligation to name any Holder that is not a Notice Holder as a selling securityholder in any Shelf Registration Statement or related Prospectus. 

(f) The parties hereto agree that the Holders of Registrable Securities will suffer damages, and that it would not be feasible to
ascertain the extent of such damages with precision, if: 
 (i) a Shelf Registration Statement has not been filed on or prior
to the Filing Deadline; 
 (ii) a Shelf Registration Statement has not been declared effective under the Securities Act on or
prior to the Effectiveness Deadline 
 (iii) a Shelf Registration Statement, if required pursuant to the last sentence of
Section 2(a), has not been delcared effective under the Securities Act on or prior to Secondary Effectiveness Deadline; 

(iv) the Company has failed to perform its obligations set forth in Section 2(e)(i) within the time period required therein;

 (v) a new Shelf Registration Statement or a post-effective amendment to a Shelf Registration Statement filed pursuant to
Section 2(e)(i) has not become effective under the Securities Act on or prior to the Amendment Effectiveness Deadline; 

(vi) a supplement to a Prospectus is required to be filed with the SEC pursuant to Section 2(e)(i) and fails to be filed with the
SEC within the prescribed period and in the manner set forth in Section 2(e) above (a date such filing is required to be made, an “Additional Filing Deadline”); or 

(vii) the aggregate duration of Deferral Periods in any period exceeds the number of days permitted in respect of such period pursuant
to Section 3(h) hereof. 

  
 Annex C-6.

 Each event described in any of the foregoing clauses (i) through (vii) is
individually referred to herein as a “Registration Default.” For purposes of this Annex C, each Registration Default set forth above shall begin and end on the dates set forth in the table set forth below: 

 

					
	 Type of

Registration
 Default by

Clause
	  	 

Beginning Date
	  	 

Ending Date

			
	(i)	  	Filing Deadline	  	the date a Shelf Registration Statement is filed
			
	(ii)	  	Effectiveness Deadline	  	the date a Shelf Registration Statement becomes effective under the Securities Act
			
	(iii)	  	Secondary Effectiveness Deadline	  	the date thereafter a Shelf Registration Statement becomes effective under the Securities Act
			
	(iv)	  	the date by which the Company is required to perform its obligations under Section 2(e)(i) (taking into account the last sentence of Section 2(e))	  	the date the Company performs its obligations set forth in Section 2(e)(i)
			
	(v)	  	the Amendment Effectiveness Deadline (taking into account the last sentence of Section 2(e))	  	the date the applicable post-effective amendment to a Shelf Registration Statement or a new Shelf Registration Statement becomes effective under the Securities Act
			
	(vi)	  	the Additional Filing Deadline	  	the date the applicable supplement to a Prospectus is filed with the SEC in the manner set forth in Section 2(e)
			
	(vii)	  	the date on which the aggregate duration of Deferral Periods in any period exceeds the number of days permitted by Section 3(h)	  	termination of the Deferral Period that caused the limit on the aggregate duration of Deferral Periods to be exceeded

 For purposes of this Annex C, Registration Defaults shall begin on the dates set forth in the table above and
shall continue until the ending dates set forth in the table above. 
 Commencing on (and including) any date that a
Registration Default has begun and ending on (but excluding) the next date on which there are no Registration Defaults that have occurred and are continuing (a “Registration Default Period”), the Company shall pay to Record

  
 Annex C-7.

 
Holders of Registrable Securities in respect of each day in the Registration Default Period, additional interest at a rate per annum equal to (i) on the Securities that are Registrable
Securities at an annual rate of 0.50% of the aggregate principal amount of such outstanding Securities and (ii) on the shares of Common Stock that have been issued upon conversion of the Securities and that are Registrable Securities at an
annual rate equal to 0.50% of an amount equal to the number of shares of such Common Stock multiplied by the quotient of $1,000 divided by the conversion rate during such periods (collectively for clauses (i) and (ii), the “Additional
Interest”); provided that in the case of a Registration Default Period that is in effect solely as a result of a Registration Default of the type described in clause (iv), (v) or (vi) of the preceding paragraph, such
Additional Interest shall be paid only to the Holders (as set forth in the succeeding paragraph) that have delivered Notices and Questionnaires that caused the Company to incur the obligations set forth in Section 2(e) the non-performance of
which is the basis of such Registration Default. Notwithstanding the foregoing, no Additional Interest shall accrue as to any Security from and after the earlier of (x) the date such security is no longer a Registrable Security and
(y) expiration of the Effectiveness Period. The rate of accrual of the Additional Interest with respect to any period shall not exceed the rate provided for in this paragraph notwithstanding the occurrence of multiple concurrent Registration
Defaults. 
 The Additional Interest shall accrue from the first day of the applicable Registration Default Period, and shall be
payable on each Interest Payment Date during the Registration Default Period (and on the Interest Payment Date next succeeding the end of the Registration Default Period if the Registration Default Period does not end on an Interest Payment Date) to
the Record Holders of the Securities entitled thereto; provided that any Additional Interest accrued with respect to any Security or portion thereof redeemed by the Company on a redemption date or purchased by the Company on a repurchase date
prior to the Interest Payment Date, shall, in any such event, be paid instead to the Holder who submitted such Security or portion thereof for redemption or repurchase on the applicable Redemption Date or repurchase date, as the case may be, on such
date, unless the Redemption Date or the Fundamental Change Repurchase Date, as the case may be, falls after the Record Date immediately preceding the Interest Payment Date and on or prior to the corresponding Interest Payment Date, in which case the
Record Holder shall receive such interest; provided further that upon conversion of any Security, the Holder or Record Holder thereof shall not be entitled to any Additional Interest except for conversions after the close of business on a
Record Date but on or prior to the opening of business on the Scheduled Trading Day immediately following the corresponding Interest Payment Date, in which case the Record Holder shall receive such Additional Interest and the converting Holder shall
be required to pay an amount equal to such interest to the Company; provided, however that no such payment need be made (i) for conversion following the Record Date immediately preceding the Stated Maturity of the Notes,
(ii) if the Company has specified a Redemption Date, (iii) if the Company has specified a Fundamental Change Repurchase Date that is after the relevant Record Date and on or prior to the second Scheduled Trading Day immediately following
the corresponding Interest Payment Date, or (iv) to the extent of any overdue Additional Interest, if any such overdue Additional Interest exists at the time of conversion with respect to such Security. The Trustee shall be entitled, on behalf
of registered holders of Securities, to seek any available remedy for the enforcement of this Annex C, including for the payment of such Additional Interest. Notwithstanding the foregoing, the parties agree that the sole damages payable for a
violation of the terms of this Annex C with respect to 

  
 Annex C-8.

 
which additional interest is expressly provided shall be such Additional Interest. Nothing shall preclude any Holder from pursuing or obtaining specific performance or other equitable relief with
respect to this Annex C. 
 All of the Company’s obligations set forth in this Section 2(f) that are
outstanding with respect to any Registrable Security at the time such security ceases to be a Registrable Security shall survive until such time as all such obligations with respect to such security have been satisfied in full (notwithstanding
termination of this Annex C pursuant to Section 8(j)). 
 The parties hereto agree that the additional interest
provided for in this Section 2(f) constitutes a reasonable estimate of the damages that may be incurred by Holders of Registrable Securities by reason of the failure of a Shelf Registration Statement to be filed or declared effective or
available for effecting resales of Registrable Securities in accordance with the provisions hereof. 
 3. Registration
Procedures. In connection with the registration obligations of the Company under Section 2 hereof, the Company shall: 
 (a) Before filing any Shelf Registration Statement or Prospectus or any amendments or supplements thereto with the SEC, furnish to the Notice Holders and the Special Counsel of such offering, if any,
copies of all such documents proposed to be filed at least two Business Days prior to the filing of such Shelf Registration Statement or amendment thereto or Prospectus or supplement thereto (other than supplements that do nothing more than name
Notice Holders and provide information with respect thereto). 
 (b) Subject to Section 3(h) prepare and file with the SEC
such amendments and post-effective amendments to each Shelf Registration Statement as may be necessary to keep such Shelf Registration Statement continuously effective during the Effectiveness Period; cause the related Prospectus to be supplemented
by any required prospectus supplement, and as so supplemented to be filed pursuant to Rule 424 (or any similar provisions then in force) under the Securities Act; and use its commercially reasonable efforts to comply with the provisions of the
Securities Act applicable to it with respect to the disposition of all securities covered by such Shelf Registration Statement during the Effectiveness Period in accordance with the intended methods of disposition by the sellers thereof set forth in
such Shelf Registration Statement as so amended or such Prospectus as so supplemented. 
 (c) As promptly as practicable give
notice to the Special Counsel, (i) when any Prospectus, prospectus supplement, Shelf Registration Statement or post-effective amendment to a Shelf Registration Statement has been filed with the SEC and, with respect to a Shelf Registration
Statement or any post-effective amendment, when the same has been declared effective (other than supplements that do nothing more than name Notice Holders and provide information with respect thereto), (ii) of any request, following the
effectiveness of the initial Shelf Registration Statement under the Securities Act, by the SEC or any other federal or state governmental authority for amendments or supplements to any Shelf Registration Statement or related Prospectus or for
additional information, (iii) of the issuance by the SEC or any other federal or state governmental authority of any stop order suspending the effectiveness of any Shelf Registration Statement or the initiation or threatening of any proceedings
for that purpose, 

  
 Annex C-9.

 
(iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in
any jurisdiction or the initiation or threatening of any proceeding for such purpose, (v) of the occurrence of, but not the nature of or details concerning, a Material Event and (vi) of the determination by the Company that a
post-effective amendment to a Shelf Registration Statement will be filed with the SEC, which notice may, at the discretion of the Company (or as required pursuant to Section 3(h)) state that it constitutes a Deferral Notice, in which event the
provisions of Section 3(h) shall apply. As promptly as practicable after the effectiveness of any Shelf Registration Statement, the Company shall issue a press release to PR Newswire announcing such effectiveness. 

(d) Use its commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of a Shelf Registration
Statement or the lifting of any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction in which they have been qualified for sale, in either case at the earliest possible
moment, and provide immediate notice to each Notice Holder of the withdrawal of any such order. 
 (e) As promptly as
practicable furnish to each Notice Holder and the Special Counsel, upon request and without charge, at least one conformed copy of each Shelf Registration Statement and any amendment thereto, including exhibits and all documents incorporated or
deemed to be incorporated therein by reference. 
 (f) During the Effectiveness Period, deliver to each Notice Holder and the
Special Counsel, in connection with any sale of Registrable Securities pursuant to a Shelf Registration Statement, without charge, copies of the Prospectus relating to such Registrable Securities (including each preliminary prospectus) and any
amendment or supplement thereto as such Notice Holder may reasonably request; and the Company hereby consents (except during such periods that a Deferral Notice is outstanding and has not been revoked) to the use of such Prospectus or each amendment
or supplement thereto by each Notice Holder in connection with any offering and sale of the Registrable Securities covered by such Prospectus or any amendment or supplement thereto in the manner set forth therein. 

(g) Prior to any public offering of the Registrable Securities pursuant to a Shelf Registration Statement, use its commercially
reasonable efforts to register or qualify or cooperate with the Notice Holders and the Special Counsel in connection with the registration or qualification (or exemption from such registration or qualification) of such Registrable Securities for
offer and sale under the securities or Blue Sky laws of such jurisdictions within the United States as any Notice Holder reasonably requests in writing (which request may be included in the Notice and Questionnaire); prior to any public offering of
the Registrable Securities pursuant to a Shelf Registration Statement, use its commercially reasonable efforts to keep each such registration or qualification (or exemption therefrom) effective during the Effectiveness Period in connection with such
Notice Holder’s offer and sale of Registrable Securities pursuant to such registration or qualification (or exemption therefrom) and do any and all other acts or things reasonably necessary or advisable to enable the disposition in such
jurisdictions of such Registrable Securities in the manner set forth in the Shelf Registration Statement and the related Prospectus; provided that the Company will not be required to (i) qualify as a foreign corporation

  
 Annex C-10.

 
or as a dealer in securities in any jurisdiction where it would not otherwise be required to qualify but for this Annex C or (ii) take any action that would subject it to general
service of process in suits or to taxation in any such jurisdiction where it is not then so subject. 
 (h) Upon (A) the
issuance by the SEC of a stop order suspending the effectiveness of a Shelf Registration Statement or the initiation of proceedings with respect to a Shelf Registration Statement under Section 8(d) or 8(e) of the Securities Act, (B) the
occurrence of any event or the existence of any fact (a “Material Event”) as a result of which a Shelf Registration Statement shall contain any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein not misleading, or any Prospectus shall contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading, or (C) the occurrence or existence of any pending corporate development that, in the reasonable discretion of the Company, makes it appropriate to suspend
the availability of a Shelf Registration Statement and the related Prospectus: 
 (i) in the case of clause (B) above, as
promptly as practicable prepare and file, if necessary pursuant to applicable law, a post-effective amendment to such Shelf Registration Statement or a supplement to the related Prospectus or any document incorporated therein by reference or file
any other required document that would be incorporated by reference into such Shelf Registration Statement and Prospectus so that such Shelf Registration Statement does not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein not misleading, and such Prospectus does not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, as thereafter delivered to the purchasers of the Registrable Securities being sold thereunder, and, in the case of a
post-effective amendment to a Shelf Registration Statement, use its commercially reasonable efforts to cause it to be declared effective as promptly as is practicable, and 
 (ii) give notice to the Special Counsel, or issue a press release announcing, that the availability of a Shelf Registration Statement is suspended (a “Deferral Notice”). 

The Company will use its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed (x) in the case of clause
(A) above, as promptly as is practicable, (y) in the case of clause (B) above, as soon as, in the sole judgment of the Company, public disclosure of such Material Event would not be prejudicial to or contrary to the interests of the
Company or, if necessary to avoid unreasonable burden or expense, as soon as practicable thereafter and (z) in the case of clause (C) above, as soon as in the reasonable discretion of the Company, such suspension is no longer appropriate.
Any such period during which the availability of the Shelf Registration Statement and any Prospectus is suspended (the “Deferral Period”) shall, without incurring any obligation to pay additional interest pursuant to
Section 2(f), not exceed 60 days in any 90-day period or an aggregate of 120 days in any 12-month period. 

  
 Annex C-11.

 (i) If requested in writing in connection with a disposition of Registrable Securities
pursuant to a Shelf Registration Statement, make reasonably available for inspection during normal business hours by a representative for the Notice Holders of such Registrable Securities, any broker-dealers, attorneys and accountants retained by
such Notice Holders, and any attorneys or other agents retained by a broker-dealer engaged by such Notice Holders, all relevant financial and other records and pertinent corporate documents and properties of the Company and its subsidiaries, and
cause the appropriate officers, directors and employees of the Company and its subsidiaries to make reasonably available for inspection during normal business hours on reasonable notice all relevant information reasonably requested by such
representative for the Notice Holders, or any such broker-dealers, attorneys or accountants in connection with such disposition, in each case as is customary for similar “due diligence” examinations; provided that such persons shall
first agree in writing with the Company that any non-public information shall be used solely for the purposes of satisfying “due diligence” obligations under the Securities Act and exercising rights under this Annex C and shall be
kept confidential by such persons, unless (i) disclosure of such information is required by court or administrative order or is necessary to respond to inquiries of regulatory authorities, (ii) such information becomes generally available
to the public other than as a result of a disclosure or failure to safeguard by any such person or (iii) such information becomes available to any such person from a source other than the Company and such source is not bound by a
confidentiality agreement, and provided further that the foregoing inspection and information gathering shall, to the greatest extent possible, be coordinated on behalf of all the Notice Holders and the other parties entitled thereto by the
Special Counsel; and provided, further, that the Company shall not be required to provide commercially sensitive materials to direct competitors of the Company. Any person legally compelled to disclose any such confidential information made
available for inspection shall as soon as practicable provide the Company with prior written notice of such requirement so that the Company may seek a protective order or other appropriate remedy and such person shall take such actions as reasonably
necessary to protect the confidentiality of such information (if practicable) to the extent such action is otherwise not inconsistent with, an impairment of or in derogation of the rights and interest of the Holder. 

(j) Comply with all applicable rules and regulations of the SEC and make generally available to its securityholders earning statements
(which need not be audited) satisfying the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder (or any similar rule promulgated under the Securities Act) for a 12-month period commencing on the first day of the first
fiscal quarter of the Company commencing after the effective date of a Shelf Registration Statement, which statements shall be made available no later than 45 days after the end of the 12-month period or 90 days if the 12-month period coincides with
the fiscal year of the Company. 
 (k) Cooperate with each Notice Holder to facilitate the timely preparation and delivery of
certificates or book-entry statements representing Registrable Securities sold or to be sold pursuant to a Shelf Registration Statement, which certificates shall not bear any restrictive legends as permitted under the Securities Act, and cause such
Registrable Securities to be in such denominations as are permitted by the Indenture and registered in such names as such Notice Holder may request in writing at least one Business Day prior to any sale of such Registrable Securities. 

  
 Annex C-12.

 (l) Provide a CUSIP number for all Registrable Securities covered by each Shelf Registration
Statement not later than the effective date of such Shelf Registration Statement and provide the Trustee and the transfer agent for the Common Stock with printed certificates or book-entry statements for the Registrable Securities that are in a form
eligible for deposit with The Depository Trust Company. 
 (m) Cooperate and assist in any filings required to be made with
FINRA. 
 (n) Cause the Underlying Common Stock covered by the Shelf Registration Statement to be listed or quoted, as the case
may be, on each securities exchange or automated quotation system on which the Common Stock is then listed or quoted. 
 4.
Holder’s Obligations. (a) Each Holder agrees, by acquisition of the Registrable Securities, that no Holder shall be entitled to sell any of such Registrable Securities pursuant to a Shelf Registration Statement or to receive
a Prospectus relating thereto, unless such Holder has furnished the Company with a Notice and Questionnaire as required pursuant to Section 2(e) hereof (including the information required to be included in such Notice and Questionnaire) and the
information set forth in the next sentence. Each Notice Holder agrees promptly to furnish to the Company all information required to be disclosed in order to make the information previously furnished to the Company by such Notice Holder not
misleading and any other information regarding such Notice Holder and the distribution of such Registrable Securities as the Company may from time to time reasonably request. Any sale of any Registrable Securities by any Holder shall constitute a
representation and warranty by such Holder that the information relating to such Holder and its plan of distribution is as set forth in the Prospectus delivered by such Holder in connection with such disposition, that such Prospectus does not as of
the time of such sale contain any untrue statement of a material fact relating to or provided by such Holder or its plan of distribution and that such Prospectus does not as of the time of such sale omit to state any material fact relating to or
provided by such Holder or its plan of distribution necessary to make the statements in such Prospectus, in the light of the circumstances under which they were made, not misleading. Each Holder further agrees not to sell any Registrable Securities
pursuant to the Shelf Registration Statement without delivering, or, if permitted by applicable securities law, making available, to the purchaser thereof a Prospectus in accordance with the requirements of applicable securities laws. Each Holder
further agrees that such Holder will not make any offer relating to the Registrable Securities pursuant to the Shelf Registration Statement that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a Free Writing
Prospectus, unless it has obtained the prior written consent of the Company. 
 (b) Upon receipt of any Deferral Notice, each
Notice Holder agrees not to sell any Registrable Securities pursuant to any Shelf Registration Statement until such Special Counsel’s receipt of copies of the supplemented or amended Prospectus provided for in Section 3(h)(i), or until it
is advised in writing by the Company that the Prospectus may be used. 
 5. Registration Expenses. The Company
shall bear all fees and expenses incurred in connection with the performance by the Company of its obligations under Sections 2 and 3 of this Annex C whether or not any Shelf Registration Statement is declared effective. Such fees and
expenses shall include, without limitation, (i) all registration and filing fees (including, 

  
 Annex C-13.

 
without limitation, fees and expenses (x) with respect to filings required to be made with FINRA and the SEC and (y) of compliance with federal and state securities or Blue Sky laws
(including, without limitation, reasonable fees and disbursements of the Special Counsel in connection with Blue Sky qualifications of the Registrable Securities under the laws of such jurisdictions as Notice Holders of a majority of the Registrable
Securities being sold pursuant to a Shelf Registration Statement may designate), (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities in a form eligible for deposit with The
Depository Trust Company), (iii) all reasonable expenses of any persons in preparing or assisting in preparing, word processing, printing and distributing any Shelf Registration Statement, any Prospectus, any amendments or supplements thereto,
and any securities sales agreements and other documents relating to the performance of and compliance with this Annex C, (iv) reasonable fees and disbursements of counsel for the Company in connection with any Shelf Registration
Statement, (v) reasonable fees and disbursements of the Trustee and its counsel and of the registrar and transfer agent for the Common Stock, (vi) Securities Act liability insurance obtained by the Company in its sole discretion and
(vii) the reasonable fees and disbursements of Special Counsel, provided that such fees shall not exceed $25,000 and supporting documentation for such fees and disbursements has been provided to the Company. In addition, the Company shall pay
the internal expenses of the Company (including, without limitation, all salaries and expenses of officers and employees performing legal or accounting duties), the expense of any annual audit, the fees and expenses incurred in connection with the
listing by the Company of the Registrable Securities on any securities exchange on which similar securities of the Company are then listed and the fees and expenses of any person, including special experts, retained by the Company. Notwithstanding
the provisions of this Section 5, each seller of Registrable Securities shall pay any broker’s commission, agency fee or underwriter’s discount or commission in connection with the sale of the Registrable Securities under a Shelf
Registration Statement. 
 6. Indemnification and Contribution. 

(a) The Company agrees to indemnify and hold harmless each Notice Holder, each person, if any, who controls any Notice Holder within the
meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act, and each affiliate of any Notice Holder within the meaning of Rule 405 under the Securities Act from and against any and all losses, claims, damages
and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim), as incurred, caused by or that are based upon or arise as of any untrue
statement or alleged untrue statement of a material fact contained in any Shelf Registration Statement or any amendment thereof, any preliminary prospectus or any Prospectus (as amended or supplemented if the Company shall have furnished any
amendments or supplements thereto) or any Issuer Free Writing Prospectus prepared by it or authorized by it in writing for use by such Notice Holder (as amended or supplemented if the Company shall have furnished any amendments or supplements
thereto), caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in the light of the circumstances under which they were made, except to
the extent such losses, claims, damages or liabilities are caused by any such untrue statement or omission or alleged untrue statement or omission based upon information relating to any Notice Holder furnished to the Company in writing by or on
behalf of such Notice Holder expressly for use therein; provided that the 

  
 Annex C-14.

 
foregoing indemnity shall not inure to the benefit of any Notice Holder (or to the benefit of any person controlling such Notice Holder) from whom the person asserting such losses, claims,
damages or liabilities purchased the Registrable Securities, if a copy of the Prospectus or the Issuer Free Writing Prospectus (both as then amended or supplemented if the Company shall have furnished any amendments or supplements thereto) was not
sent or given by or on behalf of such Notice Holder to such person, if required by law so to have been delivered at or prior to the written confirmation of the sale of the Registrable Securities to such person, and if the Prospectus or the Issuer
Free Writing Prospectus (both as so amended or supplemented) would have cured the defect giving rise to such losses, claims, damages or liabilities, unless such failure is the result of noncompliance by the Company under this Annex C.

 (b) Each Notice Holder agrees severally and not jointly to indemnify and hold harmless the Company and its directors, its
officers who sign any Shelf Registration Statement and each person, if any, who controls the Company (within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act) or any other Notice Holder, to the same
extent as the foregoing indemnity from the Company to such Notice Holder, but only (i) to the extent such losses, claims, damages or liabilities are caused by any such untrue statement or omission or alleged untrue statement or omission based
solely upon information relating to such Notice Holder furnished to the Company in writing by or on behalf of such Notice Holder expressly for use in such Shelf Registration Statement or Prospectus or amendment or supplement thereto or (ii) to
the extent that such Notice Holder fails to send or deliver a copy of the Prospectus (as then amended or supplemented if the Company shall have furnished any amendments or supplements thereto), but only if (A) the Prospectus (as so amended or
supplemented) would have cured the defect giving rise to such losses, claims, damages or liabilities and (B) such failure is not the result of noncompliance by the Company under this Annex C. In no event shall the liability of any Notice
Holder hereunder be greater in amount than the dollar amount of the net proceeds received by such Notice Holder upon the sale of the Registrable Securities pursuant to the Shelf Registration Statement giving rise to such indemnification obligation.

 (c) In case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of
which indemnity may be sought pursuant to Section 6(a) or 6(b) hereof, such person (the “indemnified party”) shall promptly notify the person against whom such indemnity may be sought (the “indemnifying party”)
in writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may designate in such
proceeding and shall pay the reasonable fees and disbursements of such counsel related to such proceeding; provided that the failure of any indemnified party to give such notice shall not relieve the indemnifying party of its obligations or
liabilities pursuant to this Annex C, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have
materially and adversely prejudiced the indemnifying party. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified party
unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel, (ii) the indemnifying party shall have failed promptly to assume

  
 Annex C-15.

 
the defense of such proceeding and to employ counsel reasonably satisfactory to such indemnified party in any such proceeding or (iii) the named parties to any such proceeding (including any
impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is understood that the
indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in
addition to any local counsel) for all such indemnified parties and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by, in the case of parties indemnified pursuant to
Section 6(a), the Holders of a majority (with Holders of Securities deemed to be the Holders, for purposes of determining such majority, of the number of shares of Underlying Common Stock into which such Securities are or would be convertible
as of the date on which such designation is made) of the Registrable Securities covered by the Shelf Registration Statement held by Holders that are indemnified parties pursuant to Section 6(a) and, in the case of parties indemnified pursuant
to Section 6(b), the Company. The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, which consent shall not be unreasonably withheld, delayed or conditioned, but if settled with
such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment. No indemnifying party shall, without
the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such
indemnified party, unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding. 

(d) To the extent that the indemnification provided for in Section 6(a) or 6(b) is unavailable to an indemnified party or
insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable
by such indemnified party as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the indemnifying party or parties on the one hand and the indemnified
party or parties on the other hand or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause
(i) above but also the relative fault of the indemnifying party or parties on the one hand and of the indemnified party or parties on the other hand in connection with the statements or omissions that resulted in such losses, claims, damages or
liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company shall be deemed to be equal to the total net proceeds from the initial issuance of the Securities to which such losses, claims,
damages or liabilities relate. The relative benefits received by any Holder shall be deemed to be equal to the value of receiving registration rights under this Annex C for the Registrable Securities. The relative fault of the Holders on the
one hand and the Company on the other hand shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information
supplied by the Holders or by the Company, and the parties’ relative intent, knowledge, access to information 

  
 Annex C-16.

 
and opportunity to correct or prevent such statement or omission. The Holders’ respective obligations to contribute pursuant to this Section 6(d) are several in proportion to the
respective number of Registrable Securities they have sold pursuant to a Shelf Registration Statement, and not joint. 
 The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 6(d) were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable
considerations referred to in the immediately preceding paragraph. The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities referred to in the immediately preceding paragraph shall be deemed to
include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding this Section 6(d), no
indemnifying party that is a selling Holder shall be required to contribute any amount in excess of the amount by which the net proceeds received by such Holder from the sale of the Registrable Securities giving rise to the indemnification
obligation exceeds the amount of any damages that such indemnifying party has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. 
 (e) The remedies provided for in this Section 6 are not exclusive and shall not limit any rights or remedies which may otherwise be available to an indemnified party at law or in equity, hereunder,
under the Purchase Agreement or otherwise. 
 (f) The indemnity and contribution provisions contained in this Section 6
shall remain operative and in full force and effect regardless of (i) any termination of this Annex C, (ii) any investigation made by or on behalf of any Holder, any person controlling any Holder or any affiliate of any Holder or by
or on behalf of the Company, its officers or directors or any person controlling the Company and (iii) the sale of any Registrable Securities by any Holder pursuant to the Shelf Registration Statement. 

7. [Reserved]. 
 8. Miscellaneous. 
 (a) No Conflicting Agreements. The
Company is not, as of the date hereof, a party to, nor shall it, on or after the date of this Annex C, enter into, any agreement with respect to its securities that conflicts with the rights granted to the Holders in this Annex C. The
Company represents and warrants that the rights granted to the Holders hereunder do not in any way conflict with the rights granted to the holders of the Company’s securities under any other agreements. 

(b) Amendments and Waivers. The provisions of this Annex C, including the provisions of this sentence, may not be
amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the Company has obtained the written consent of Holders of a majority of the then outstanding

  
 Annex C-17.

 
Underlying Common Stock constituting Registrable Securities (with Holders of Securities deemed to be the Holders, for purposes of this Section, of the number of outstanding shares of Underlying
Common Stock into which such Securities are or would be convertible as of the date on which such consent is requested). Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates
exclusively to the rights of Holders whose securities are being sold pursuant to a Shelf Registration Statement and that does not directly or indirectly affect the rights of other Holders may be given by Holders of at least a majority of the
Registrable Securities being sold by such Holders pursuant to such Shelf Registration Statement; provided that the provisions of this sentence may not be amended, modified or supplemented except in accordance with the provisions of the
immediately preceding sentence. Each Holder of Registrable Securities outstanding at the time of any such amendment, modification, supplement, waiver or consent or thereafter shall be bound by any such amendment, modification, supplement, waiver or
consent effected pursuant to this Section 8(b) whether or not any notice, writing or marking indicating such amendment, modification, supplement, waiver or consent appears on the Registrable Securities or is delivered to such Holder.

 (c) Notices. All notices and other communications provided for or permitted under this Annex C shall be made in
writing by hand delivery, by fax, by courier or by first-class mail, return receipt requested, and shall be deemed given (i) when made, if made by hand delivery, (ii) upon confirmation, if made by telecopier, (iii) one Business Day
after being deposited with such courier, if made by overnight courier or (iv) on the date indicated on the notice of receipt, if made by first-class mail, to the parties as follows: 

(i) if to a Holder, at the most current address given by such Holder to the Company in a Notice and Questionnaire or any amendment
thereto; 
 (ii) if to the Company, to: 
 OPKO Health, Inc. 
 4400 Biscayne Blvd. 

Miami, Florida 33137 
 Attention: Kate Inman, Deputy General Counsel 
 E-mail: kinman@opko.com

 Facsimile: (305) 575-4140 
 with a copy to: 
 Akerman Senterfitt 

One Southeast Third Avenue 
 25th Floor

 Miami, Florida 33131 
 Attention: Teddy D. Klinghoffer, Esq. 
 E-mail:
teddy.klinghoffer@akerman.com 
 Attention: Esther L. Moreno, Esq. 

E-mail: esther.moreno@akerman.com 
 Facsimile: (305) 374-5095 
 or to such other person at such other place as the
Company shall designate to the Holders in writing. 

  
 Annex C-18.

 (d) Approval of Holders. Whenever the consent or approval of Holders of a specified
percentage of Registrable Securities is required hereunder, Registrable Securities held by the Company or its affiliates (as such term is defined in Rule 405 under the Securities Act) (other than Holders if such Holders are deemed to be such
affiliates solely by reason of their holdings of such Registrable Securities or other securities of the Company) shall not be counted in determining whether such consent or approval was given by the Holders of such required percentage. 

(e) Successors and Assigns. Any person who purchases any Registrable Securities from any Purchaser shall be deemed, for
purposes of this Annex C, to be an assignee of such Purchaser. This Annex C shall inure to the benefit of and be binding upon the successors and assigns of each of the parties and shall inure to the benefit of and be binding upon each
Holder of any Registrable Securities, provided that nothing herein shall be deemed to permit any assignment, transfer or other disposition of Registrable Securities in violation of the terms of the Indenture. If any transferee of any Holder
shall acquire Registrable Securities, in any manner, whether by operation of law or otherwise, such Registrable Securities shall be held subject to all of the terms of this Annex C, and by taking and holding such Registrable Securities, such
person shall be conclusively deemed to have agreed to be bound by and to perform all of the terms and provisions of this Annex C and such person shall be entitled to receive the benefits hereof. 

(f) Headings; Section References. The headings in this Annex C are for convenience of reference only and shall not
limit or otherwise affect the meaning hereof. Unless otherwise specified, section references in this Annex C shall be to sections of this Annex C and not to the Purchase Agreement. 

(g) Governing Law. THIS ANNEX C SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

 (h) Severability. If any term, provision, covenant or restriction of this Annex C is held to be invalid,
illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated thereby, and the parties hereto shall
use their best efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction, it being intended that all of the rights and privileges of the
parties shall be enforceable to the fullest extent permitted by law. 
 (i) Entire Agreement. This Annex C is
intended by the parties as a final expression of their agreement and is intended to be a complete and exclusive statement of the agreement and understanding of the parties hereto in respect of the subject matter contained herein and the registration
rights granted by the Company with respect to the Registrable 

  
 Annex C-19.

 
Securities. Except as provided in the Purchase Agreement, there are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein, with respect to the
registration rights granted by the Company with respect to the Registrable Securities. This Annex C supersedes all prior agreements and undertakings among the parties with respect to such registration rights. No party hereto shall have any
rights, duties or obligations other than those specifically set forth in this Annex C. In no event will such methods of distribution take the form of an underwritten offering of the Registrable Securities without the prior agreement of the
Company. 
 (j) Termination. This Annex C and the obligations of the parties hereunder shall terminate upon
the end of the Effectiveness Period, except for any liabilities or obligations under Section 4, 5 or 6 hereof, any confidentiality obligations under Section 3(i) hereof, and the obligations to make payments of and provide for additional
interest under Section 2(f) hereof to the extent such additional interest accrues prior to the end of the Effectiveness Period, each of which shall remain in effect in accordance with its terms. 

[Remainder of Page Left Intentionally Blank] 

  
 Annex C-20.

 ANNEX D 
 FORM OF INDENTURE 
 Attached 

  
 Annex D

 ANNEX E 
 Form of Opinion of Akerman Senterfitt 
 Corporate counsel for the Company shall
deliver an opinion substantially similar in substance as follows. 
 As used herein the following terms have the respective
meanings set forth below: 
 “Applicable Agreements” means the agreements filed as exhibits to the SEC Reports
(as defined in the Note Purchase Agreement). 
 “Applicable Orders” means every judgment, order, writ,
injunction or decree of any arbitral panel, court or other Governmental Authority by which the Company or any of its properties is bound and that is material in relation to the business, operations, affairs, financial condition, assets, or
properties of the Company, as certified to us by an officer of the Company. 
 “Company Bylaws” means the
Company’s Amended and Restated Bylaws. 
 “Company Certificate of Incorporation” means the Company’s
Amended and Restated Certificate of Incorporation. 
 “DGCL” means the Delaware General Corporation Law.

 “Governmental Approval” means any consent, approval, license, authorization or validation of, or filing,
recording or registration with, any Governmental Authority pursuant to applicable laws of the State of New York, the applicable laws of the State of Florida, the DGCL or the applicable laws of the United States of America. 

“Governmental Authority” means any executive, legislative, judicial, administrative or regulatory body of the State of
New York, the State of Florida, the State of Delaware or the United States of America. 
 “Opinion Documents”
means, collectively, (i) the Note Purchase Agreement, (ii) the Notes, and (iii) the Indenture. 

“Organizational Documents” means, collectively, the Company Certificate of Incorporation and the Company Bylaws.

 “Person” has the meaning given to such term in the Note Purchase Agreement. 

“Placement Memorandum” has the meaning given to such term in the Note Purchase Agreement. 

  
 Annex E

 Based upon the foregoing and subject to the limitations, qualifications, exceptions and assumptions set
forth herein, we are of the opinion that: 
  

	 	1.	The Company is validly existing as a corporation and in good standing under the laws of the State of Delaware, and has the corporate power and authority to own its
properties and conduct its business as described in the Placement Memorandum. 

  

	 	2.	The authorized capital stock of the Company conforms in all material respects as to legal matters to the description thereof contained in the “Description of
Capital Stock” section in the Placement Memorandum. The form of certificate used to evidence the Conversion Shares complies with all applicable requirements of the Organizational Documents and DGCL. 

 

	 	3.	The Company has the corporate power and authority under the laws of the State of Delaware to execute and deliver the Opinion Documents to which it is a party and
perform all of its obligations under such Opinion Documents. The execution and delivery of such Opinion Documents and the performance by the Company of its obligations thereunder have been duly authorized by all requisite corporate action.

  

	 	4.	Each Opinion Document has been duly executed and delivered by or on behalf of the Company. 

 

	 	5.	None of the execution and delivery of the Opinion Documents to which the Company is a party, nor the performance by the Company of its obligations thereunder will
(i) violate the Company’s Organizational Documents; (ii) constitute a breach or violation of, or a default under, any Applicable Agreement; (iii) result in the imposition of any lien, charge or encumbrance upon any property or
assets of the Company pursuant to any Applicable Agreement; (iv) result in the contravention of any Applicable Order; or (v) violate any applicable law of the State of New York, any applicable law of the State of Florida, the DGCL, or any
applicable law of the United States of America. 

  

	 	6.	The statements in the “Description of Notes” and “Description of Capital Stock” sections in the Placement Memorandum, to the extent that such
information purports to constitute a summary of the documents and securities referred to therein, constitute accurate and complete summaries of such documents and securities in all material respects. 

 

	 	7.	The statements in the “Certain United States Federal Income Tax Considerations” and “Certain ERISA Considerations” sections in the Placement
Memorandum, insofar as such statements purport to summarize certain federal income tax laws of the United States or ERISA considerations, constitute accurate summaries of the principal U.S. federal income tax and ERISA consequences of an investment
in the Notes in all material respects. 

  

	 	8.	Each of the Note Purchase Agreement and the Indenture constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance
with its terms under applicable laws of the State of New York. 

  
 Annex E-2.

	 	9.	When authenticated by the Trustee in the manner provided in the Indenture and paid for by the Purchasers and delivered in accordance with the Note Purchase Agreement,
the Notes will constitute valid and binding obligations of the Company, entitled to the benefits of the Indenture and enforceable against the Company in accordance with their terms, under applicable laws of the State of New York.

  

	 	10.	No Governmental Approval is required to authorize, or is required in connection with, the issuance of the Notes (and the Conversion Shares into which the Notes are
convertible) by the Company or the execution, delivery or performance of any of the Opinion Documents by the Company, or the enforceability of any of the Opinion Documents against the Company, except for those Governmental Approvals that have been
obtained or taken and are in full force and effect, and any filings, applications or notices as may be required with The New York Stock Exchange in connection with the listing of the Conversion Shares and any state blue sky authority, as to which we
do not express any opinions. 

  

	 	11.	The Company is not, and, after giving effect to the offer and sale of the Notes and the use of the proceeds in accordance with the terms of the Agreement, will not be,
an “investment company,” as such term is defined in the Investment Company Act of 1940, as amended, and the applicable rules and regulations thereunder. 

 

	 	12.	Assuming as to factual matters, without investigation, that the representations, warranties and covenants of the Company in Section 2 of the Note Purchase
Agreement and of the Purchasers in Section 3 of the Note Purchase Agreement are true and correct, (a) the offer, issuance, sale and delivery by the Company of the Notes to the Purchasers in the manner contemplated by the Note Purchase
Agreement, and (b) the issuance of the Conversion Shares upon the conversion of the Notes in the manner contemplated by the Indenture, do not require registration under the Securities Act of 1933, as amended (the “Securities Act”),
and the applicable rules and regulations thereunder, and do not require qualification of the Indenture under the Trust Indenture Act of 1939, as amended; provided, however, that we express no opinion as to any subsequent offer or resale or other
transfer of any Notes or any Conversion Shares into which the Notes are convertible. 

  

	 	13.	The Conversion Shares that the Purchasers are entitled to be issued upon conversion of the Notes have been duly authorized on behalf of the Company and reserved for
issuance upon such conversion and, the Conversion Shares, if and when issued upon conversion of the Notes in accordance with the terms of the Indenture and the Notes will be validly issued, fully paid and nonassessable. 

 

	 	14.	The holders of outstanding shares of Common Stock are not entitled to any preemptive rights under the Organizational Documents or the DGCL to subscribe for the Notes or
the Conversion Shares into which the Notes are convertible. 

  
 Annex E-3.

	 	15.	The authorized capital stock of the Company, as of the open of business on the date hereof, consisted of (a) 500,000,000 shares of Common Stock, and
(b) 10,000,000 shares of Preferred Stock. 

  

	 	16.	Neither the issuance of the Notes (and the Conversion Shares into which the Notes are convertible) nor the intended use of the proceeds thereof will violate Regulations
T, U or X of the Board of Governors of the Federal Reserve System. 

  
 Annex E-4.

 ANNEX F 
 Form of Lock-Up Agreement 
 January    , 2013

 Jefferies & Company, Inc. 

520 Madison Avenue 
 New York, New York 10022

 RE: OPKO Health, Inc. (the “Company”) 
 Ladies & Gentlemen: 
 The undersigned is an owner of record or
beneficially of certain shares of common stock, par value $0.01 per share, of the Company (“Shares”) or securities convertible into or exchangeable or exercisable for Shares. The Company proposes to carry out a private offering of
$150,000,000 aggregate principal amount of Convertible Notes due 2033 (the “Offering”) for which Jefferies & Company, Inc. will act as placement agent (the “Placement Agent”). The undersigned recognizes
that the Offering will be of benefit to the undersigned and will benefit the Company by, among other things, raising additional capital for its operations. The undersigned acknowledges that you are relying on the representations and agreements of
the undersigned contained in this letter agreement in carrying out the Offering. 
 In consideration of the foregoing, the
undersigned hereby agrees that the undersigned will not, and will cause any spouse or immediate family member of the spouse or the undersigned living in the undersigned’s household not to, without the prior written consent of the Placement
Agent (which consent may be withheld in its sole discretion), directly or indirectly, sell, offer, contract or grant any option to sell (including without limitation any short sale), pledge, transfer, establish an open “put equivalent
position” within the meaning of Rule 16a-1(h) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise dispose of any Shares, options or warrants to acquire Shares, or securities
exchangeable or exercisable for or convertible into Shares currently or hereafter owned either of record or beneficially (as defined in Rule 13d-3 under the Exchange Act) by the undersigned (or such spouse or family member), or publicly
announce an intention to do any of the foregoing, for a period commencing on the date hereof and continuing through the close of trading on the date 90 days after the date of the purchase agreements relating to the Offering to which the Company
is a party (the “Lock-up Period”); provided, that the foregoing restrictions shall not apply to the transfer of any or all of the Shares owned by the undersigned, either during the undersigned’s lifetime or on death, by gift,
will or intestate succession to the immediate family of the undersigned or to a trust the beneficiaries of which are exclusively the undersigned and/or a member or members of the undersigned’s immediate family; provided, however, that in any
such case, it shall be a condition to such transfer that the transferee executes and delivers to the Placement Agent an agreement stating that the transferee is receiving and holding the Shares subject to the provisions of this letter agreement, and
there shall be no further transfer of such Shares, except in accordance with this letter agreement. For the purposes of this paragraph, “immediate family” shall mean the 

  
 Annex F

 
spouse, domestic partner, lineal descendant (including adopted children), father, mother, brother or sister of the transferor. The restrictions set forth in this letter agreement shall not apply
to the establishment of a trading plan that complies with Rule 10b5-1 under the Exchange Act; provided, however, that no sales shall be made pursuant to such trading plan during the Lock-up Period and there shall be no public disclosure or
announcement made of such trading plan nor any filing made under the Exchange Act with respect thereto during the Lock-up Period. 
 The undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of Shares or securities convertible into or
exchangeable or exercisable for Shares held by the undersigned except in compliance with the foregoing restrictions. 
 This
agreement is irrevocable and will be binding on the undersigned and the respective successors, heirs, personal representatives, and assigns of the undersigned. However, it is understood that, if (i) the Company notifies the Placement Agent in
writing that it does not intend to proceed with the Offering, or (ii) if the purchase agreements relating to the Offering (other than the provisions thereof which survive termination) shall terminate or be terminated for any reason prior to
payment for and delivery of the Notes to be sold thereunder, this letter agreement shall immediately be terminated and the undersigned shall automatically be released from all of the obligations under this letter agreement. 

 

			
	Printed Name of Holder
		
	By:	 	  

	                Signature
	
	  

	Printed Name of Person Signing
	
	(and indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)

  
 Annex F-2.exh10_1.htm

 

Execution Copy

 

 

EMPLOYMENT AGREEMENT

 

 

THIS EMPLOYMENT AGREEMENT (this "Agreement") dated as of January 25, 2013, is entered into by and between The Middleby Corporation, a Delaware corporation (the "Company"), Middleby Marshall Inc., a Delaware corporation ("MMI"), (collectively the "Employer"), and Selim A. Bassoul ("Employee").

 

R E C I T A L:

 

The Employer is a party to an employment agreement with Employee dated December 23, 2004, as amended as of December 31, 2008, and as extended by letter agreement dated February 28, 2012 (the "Prior Agreement").

 

The Employer desires to continue and extend the term of employment of Employee as President and Chief Executive Officer of the Company and MMI, and to have Employee serve as the Chairman of the Board of Directors of the Company, and Employee desires to serve the Employer in such capacities, all on the terms and conditions hereinafter provided.

 

NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, Employee's employment by the Employer, the compensation to be paid Employee while employed by the Employer, and other good and valuable consideration, the receipt and sufficiency of which is acknowledged, the parties agree as follows:

 

	
1.

	 	
Employment.  The Employer agrees to employ Employee and Employee agrees to be employed by the Employer subject to the terms and provisions of the Agreement.

	 	 	 
	
2.

	 	
Term.  The employment of Employee by the Employer under this Agreement as provided in Section 1 will be for a period commencing on January 25, 2013 (the "Effective Date") and ending at the end of the calendar day on December 31, 2017, unless sooner terminated as hereinafter provided.

	 	 	 
	
3.

	 	
Duties.  Employee shall serve as President and Chief Executive Officer of the Company and as President and Chief Executive Officer of MMI, and shall have such powers and duties consistent with such positions as may be from time to time prescribed by the Board of Directors of the Company or MMI, as applicable.  During the term of this Agreement, the Employer agrees to nominate Employee to serve on the Board of Directors of the Company and to elect Employee to serve as Chairman if elected to the Board of Directors by the stockholders of the Company.  For the avoidance of doubt, the failure of Employee to be elected to the Board of Directors of the Company by its stockholders shall not constitute a diminution of Employee’s duties under this Agreement for purposes of Section 5(f) hereof, provided that the failure of the Board of Directors to satisfy its obligations under this Section 3 shall constitute such a diminution of Employee’s duties.  Employee shall devote substantially all of his time and effort as reasonably may be required for him to perform the duties and responsibilities to be performed by him under the terms of this Agreement.

 

 

  

  

  

 

	
4.

	 	
Compensation.

	 	 	 	 	 
	  	 	
(a)

	 	
Base Salary.  Employee shall be entitled to receive an annual base salary of One Million Dollars, subject to any increase but not decrease during the term of the Agreement.

	 	 	 	 	 
	  	 	
(b)

	 	
Incentive Compensation.  Employee shall be eligible to participate in the Value Creation Incentive Plan previously adopted by the Company, subject to all terms and conditions thereof, including, without limitation the annual award limits set forth therein.

	 	 	 	 	 
	  	 	
(c)

	 	
Expense Reimbursement.  Employer shall reimburse Employee for those reasonable legal and consulting expenses incurred by him for personal financial, tax and estate planning purposes, provided that the reimbursement of the legal fees  incurred by Employee in connection with his review of this Agreement shall not exceed $15,000.

	 	 	 	 	 
	  	 	
(d)

	 	
Automobile.  The Employer shall lease Employee an automobile of his choice and the Employer shall pay all applicable taxes, insurance, fees and expenses associated therewith.  Employee shall be entitled to a new leased automobile every two (2) years.

	 	 	 	 	 
	  	 	
(e)

	 	
Employee Benefits.  Employee shall be provided with the employee benefits maintained by the Employer for the benefit of similarly situated employees of the Employer, as in effect from time to time.

	 	 	 	 	 
	
5.

	 	
Termination.

	 	 	 
	  	 	
(a)

	 	
Employee's employment hereunder may be terminated by the Employer or by Employee at any time, or by the death of Employee.  Such termination shall automatically terminate all of the Employer's obligations not theretofore accrued under this Agreement other than as specifically set forth in this Agreement or in any employee benefit plan, program or arrangement in which Employee participates.  If the Employer terminates Employee's employment under this Agreement (as hereafter amended or extended) without "Cause," as defined below, or if employment is terminated due to Employee's death or disability, incentive compensation under the Value Creation Incentive Plan for any year shall be deemed to have accrued as of the date of termination if and to the extent that incentive compensation under the Value Creation Incentive Plan would have been payable to Employee if he had been employed on the last day of such fiscal year and shall be (i) pro rated based on the number of days that Employee was employed during the fiscal year and (ii) payable in the following fiscal year, on the earlier of March 15 or at the same time as incentive compensation under the Value Creation Incentive Plan for such year is paid to those employees who are still employed by the Employer.

	 	 	 	 	 
	  	 	
(b)

	 	
Notwithstanding anything to the contrary contained in this Agreement, in the event that (i) the Employer terminates Employee's employment under this

 

  

2

  

 

Agreement (as hereafter amended or extended) without "Cause," as defined below, (for this purpose, not including termination due to Employee's death or disability) or (ii) Employee terminates his employment under the circumstances set forth in Section 5(f), by providing written notice of such termination to the Employer, Employee shall be entitled to a lump sum amount equal to three (3) times the sum of (A) Employee's annual base salary as in effect immediately prior to the date of the termination and (B) the greater of (x) the amount of Employee's incentive compensation under the Value Creation Incentive Plan with respect to the full calendar year immediately prior to the date of the termination and (y) the average of Employee's incentive compensation under the Value Creation Incentive Plan (or, if applicable, the Management Incentive Compensation Plan previously in effect) for each of the three calendar years immediately prior to the date of the termination, payable in one lump sum within thirty (30) days of the date of termination; provided that the gross amount payable pursuant to this Section 5(b) shall not exceed Thirteen Million Five Hundred Thousand Dollars ($13,500,000).

 

	  	
(c)

	 	
Notwithstanding anything to the contrary contained in this Agreement, in the event that Employee's employment with the Employer terminates for any reason or no reason, then, in any such event Employee shall be entitled to continued worldwide participation by Employee and any dependents who were participating immediately prior to Employee's termination of employment, in all health and medical plans and programs which the Employer maintains, from time to time, for its senior executives and their dependents, under the same terms and conditions, including Employee's payment of any required employee contributions therefor, as may generally apply (including any limitation or termination of coverage of non-spouse dependents after a stated age), until the later of the death of Employee or Employee's surviving spouse to whom he was married at the time of termination of employment, provided that such participation in the Employer plans and programs is permitted under the provisions of such Employer plans and programs, and provided, further, that at such time as Employee, or any covered dependent of Employee, becomes eligible for health or medical benefits under Title XVIII of the Social Security Act (Medicare) or any governmental program in replacement thereof, such health or medical benefits shall automatically become the primary coverage for such person(s) and the coverage provided hereunder shall be secondary to such other coverage, to the maximum extent permitted under applicable law.  If, while eligible for benefits under this Subsection 5(c), Employee becomes employed by any person and becomes eligible for health and medical benefits under such employer's health plan, the Employer shall be relieved, during the period of such employment and to the extent of the benefits for which Employee and his dependents are eligible under such employer's plan, of the obligation to provide the health and medical benefits described in this Subsection 5(c).  In the event that participation in any such Employer plan or program is barred or otherwise not permitted, the Employer shall provide substantially similar health and medical benefits to Employee and any eligible dependents, in which case the Employer may self-fund such benefits or may purchase individual policies or plans to provide such benefits, in its sole discretion.  Notwithstanding anything to the contrary contained herein, in the

  

3

  

 

	 	 	 	
event that the provision of the coverage provided under this Section 5(c) would result in adverse tax consequences to the Company or Employee pursuant to Section 105(h) of the Internal Revenue Code of 1986, as amended (the “Code”), Section 4980D of the Code or other applicable law, the parties agree to cooperate such that the coverage provided by this Section 5(c) or other arrangement agreed between the parties intended to provide the substantially the same economic benefits may be provided without such adverse tax consequences.

	 	 	 	 
	  	
(d)

	 	
For purposes of this Agreement, the term "Cause" shall mean termination of Employee’s employment due to his willful misconduct in respect of his obligations to the Company occurring during the course of his employment, including violations of the Company's code of conduct or code of ethics, which in either case results in or would reasonably be expected to result in material damage to the property, business or reputation of the Company or its affiliates; provided, however, that in no event shall unsatisfactory job performance alone be deemed to be Cause; and provided, further, that, to the extent curable, Employee shall have 30 calendar days after receiving written notice from the Company in which to cure any of the actions or inactions that would otherwise result in Cause. 

	 	 	 	 
	  	
(e)

	 	
For purposes of this Agreement, a "Change in Control" shall occur on the date on which:

	 	 	 	 
	  	  	 	
(i)

	 	
Any Person (as defined below) becomes the beneficial owner directly or indirectly (within the meaning of Rule 13d-3 under the Exchange Act) of more than 35% of the Company's then outstanding voting securities (measured on the basis of voting power), not including in the securities beneficially owned by such Person any securities ac­quired directly from the Company;

	 	 	 	 	 	 
	  	  	 	
(ii)

	 	
There is consummated a merger or consolidation, other than (i) a merger or consolidation immediately following which the voting securities of the Company outstanding immediately prior thereto continue to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof), in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Company, at least 50% of the combined voting power of the voting securities of the Company, such surviving entity or any parent thereof outstanding immediately after such merger or consolidation, or (ii) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no Person acquires more than 35% of the combined voting power of the Company's then outstanding securities;

	 	 	 	 	 	 
	  	  	 	
(iii)

	 	
individuals who, as of the Effective Date, constituted the Board (the "Incumbent Board") cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the Effective Date whose election, or nomination for

 

 

  

4

  

 

	  	  	 	  	 	
election by the Company's stockholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding for this purpose any such individual whose initial assumption of office occurs as a result of either an actual or threatened election contest (as such terms are used in Rule 14a-11 of Regulation 14A promulgated under the Exchange Act) or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or

	 	 	 	 	 	 
	  	  	 	
(iv)

	 	
the stockholders of the Company approve a plan of complete liquidation or dissolution of the Company or there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets.

	 	 	 	 	 	 
	  	  	 	
Notwithstanding the foregoing, a "Change in Control" shall not be deemed to have occurred by virtue of the consummation of any transaction or series of integrated transactions immediately following which the record holders of the common stock of the Company immediately prior to such transaction or series of transactions continue to have substantially the same proportionate ownership in an entity which owns all or substantially all of the assets of the Company immediately following such transaction or series of transactions.  "Person" shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof; however, a Person shall not include (w) the Company or any of its subsidiaries, (x) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its subsidiaries, (y) an underwriter temporarily holding securities pursuant to an offering of such securities, or (z) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of the common stock of the Company.

	 	 	 	 
	  	
(f)

	 	
If the duties assigned by the Employer to Employee are materially diminished, or become inconsistent with those assigned to a Chief Executive Officer and President of a similarly situated publicly traded company, or if Employee's title of Chief Executive Officer and President is changed and such change in duties or title is not cured by the Employer within ten (10) days following receipt by the Board of written notice from Employee, such change in duties or title shall be deemed a termination by the Employer of Employee's employment without Cause, pursuant to the terms of this Agreement, and Employee shall be entitled to resign his employment hereunder and to thereafter receive all rights, benefits and payments set forth in Sections 5(a), (b) and (c).

	 	 	 	 
	  	
(g)

	 	
Notwithstanding anything to the contrary contained herein (or any other agreement entered into by and between the Employer and Employee or any incentive arrangement or plan offered by the Company), in the event that any amount or benefit paid or distributed to Employee pursuant to this Agreement, taken together with any amounts or benefits otherwise paid to Employee by the

 

 

  

5

  

 

	  	 	  	 	
Employer (collectively, the “Covered Payments”), would constitute an “excess parachute payment” as defined in Section 280G of the Code, and would thereby subject Employee to an excise tax under Section 4999 of the Code (an “Excise Tax”), the provisions of this Section 5(g) shall apply.  If the aggregate present value (as determined for purposes of Section 280G of the Code) of the Covered Payments exceeds the amount which can be paid to Employee without Employee incurring an Excise Tax, then, solely to the extent that Employee would be better off on an after tax basis by receiving the maximum amount which may be paid hereunder without Employee becoming subject to the Excise Tax, as determined by Employee in his sole discretion, the amounts payable to Employee under this Agreement (or any other agreement by and between the Employee and Employee or pursuant to any incentive arrangement or plan offered by the Company) shall be reduced (but not below zero) to the maximum amount which may be paid hereunder without Employee becoming subject to the Excise Tax (such reduced payments to be referred to as the “Payment Cap”).  In the event Employee receives reduced payments and benefits as a result of application of this Section 5(g), Employee shall have the right to designate which of the payments and benefits otherwise set forth herein (or any other agreement between the Company and Employee or any incentive arrangement or plan offered by the Company) shall be received in connection with the application of the Payment Cap, subject to the following sentence.  Reduction shall first be made from payments and benefits which are determined not to be nonqualified deferred compensation for purposes of Section 409A of the Code, and then shall be made (to the extent necessary) out of payments and benefits which are subject to Section 409A of the Code and which are due at the latest future date.

	 	 	 	 	 
	
6.

	 	
Retirement.  Employee shall be eligible to participate in the tax-qualified retirement plans maintained from time to time by Employer for the benefit of its employees, including executives and key management employees (the "Qualified Plans").  In addition, subject to the provisions hereof, Employer shall provide Employee with a supplemental retirement benefit as described below.  Exhibit A hereto illustrates the monthly supplemental retirement benefit that would become payable to Employee in accordance with the provisions of Sections 6(a), (b) and (c) below based on the retirement of Employee on or after the attainment of age 55.

	 	 	 
	  	 	
(a)

	 	
Retirement Benefits.  Upon Employee's retirement on or after the date on which he attains the age of 55 (the "Early Retirement Date"), but in no event prior thereto, Employee shall be fully vested in a monthly retirement benefit (the “Age 55 Retirement Benefit”) equal to one-twelfth of 50% of Employee's then current base salary (the “Retirement Salary”), payable for the remainder of his life.  Upon Employee's retirement on or after the date on which he attains the age of 60 (the "Normal Retirement Date"), Employee shall be fully vested in a monthly retirement benefit equal to one-twelfth of 62.5% of the Retirement Salary, in lieu of the Age 55 Retirement Benefit, payable for the remainder of his life.  Such benefit shall hereinafter be referred to as the "Age 60 Retirement Benefit".  Upon Employee's retirement on or after  the date on which he attains the age of 65 (the "Deferred Retirement Date"), Employee shall be fully vested in a monthly

 

 

  

6

  

 

 

	  	  	 	
retirement benefit equal to one-twelfth of 75% of the Retirement Salary, in lieu of the Age 60 Retirement Benefit, payable for the remainder of his life.  Such benefit shall hereinafter be referred to as the "Age 65 Retirement Benefit".

	 	 	 	 
	  	
(b)

	 	
Retirement After the Early Retirement Date But Prior to the Normal Retirement Date.  Notwithstanding the foregoing, in the event that Employee retires from employment after the Early Retirement Date but prior to the Normal Retirement Date, in addition to the Age 55 Retirement Benefit, Employee shall become vested in an additional amount equal to the difference between the Age 55 Retirement Benefit and the Age 60 Retirement Benefit multiplied by a fraction, the denominator of which is the number of full months between the date on which Employee would attain the age of 55 and the date on which Employee would attain the age of 60, and the numerator of which is the number of full months worked by Employee on and after the date Employee attains age 55 through the date of termination.

	 	 	 	 
	  	
(c)

	 	
Retirement After the Normal Retirement Date But Prior to the Deferred Retirement Date.  Notwithstanding the foregoing, in the event that Employee retires from employment after the Normal Retirement Date but prior to the Deferred Retirement Date, in addition to the Age 60 Retirement Benefit, Employee shall become vested in an additional amount equal to the difference between the Age 60 Retirement Benefit and the Age 65 Retirement Benefit multiplied by a fraction, the denominator of which is the number of full months between the date on which Employee would attain the age of 60 and the date on which Employee would attain the age of 65, and the numerator of which is the number of full months worked by Employee on and after the date Employee attains age 60 through the date of termination.

	 	 	 	 
	  	
(d)

	 	
Time of Payment of Retirement Benefit.  Upon Employee's retirement on or after the Early Retirement Date, subject to the provisions of Section 6(g), Employer shall commence payment of the monthly supplemental retirement benefit, as applicable, as of the end of the month in which such retirement occurs, and shall make each monthly payment at the end of each month thereafter.  For purposes of this Section 6, the term "retirement" shall mean Employee's separation from service for any reason or no reason (other than due to death) on or after Early Retirement Date (i.e., the date on which Employee attains age 55).  For the avoidance of doubt, for purposes of this Section 6(d), the end of the month shall mean the last business day of the month.

	 	 	 	 
	  	
(e)

	 	
Payment of Retirement Benefit Upon Employee’s Death.  In the event of Employee's death, either prior to or after the commencement of payments pursuant to this Section 6 (but prior to Employee attaining the age of 75 years), the applicable supplemental retirement benefits shall be paid (or shall continue to be paid, if already in pay status) to such beneficiary as Employee shall designate in writing (or in the absence of such designation, to his estate) in a lump sum cash payment equal to the present value of Employee's supplemental retirement benefit determined under subparagraphs (a), (b) or (c) above, as applicable, as reasonably

	 	 	 	 

 

 

  

7

  

 

 

	  	 	  	 	
determined by the Employer and assuming that Employee had lived until attaining the age of 75 years, payable on the first day of the first month following the date of Employee's death.

	 	 	 	 	 
	  	 	
(f)

	 	
Title to and beneficial ownership of any assets, whether cash or investments which Employer may set aside or earmark to meet its obligations hereunder, shall at all times remain with Employer and neither Employee nor any beneficiary shall under any circumstances acquire any property interest in any specific assets of Employer.  Nothing contained in this Agreement shall create or be construed to create a trust of any kind, or a fiduciary relationship between Employer and Employee or any other person.  To the extent that Employee is entitled to receive payments from Employer hereunder, such right shall be no greater than that of an unsecured general creditor of Employer.

	 	 	 	 	 
	  	 	
(g)

	 	
This Section 6 is intended to comply with the provisions of Section 409A of the Code and shall be construed in accordance therewith.  Notwithstanding anything to the contrary contained herein, if Employee is a Specified Employee (as defined in Section 409A of the Code) at the time he would otherwise be entitled to receive any payment hereunder, no distributions shall be made hereunder until the earliest date permitted by Section 409A(a)(2) of the Code.

	 	 	 	 	 
	
7.

	 	
Payments/Withholding.  Payment of all compensation and benefits to Employee hereunder shall be made in accordance with the relevant policies of the Employer in effect from time to time and shall be subject to all applicable employment and withholding taxes.

	 	 	 
	
8.

	 	
Successors.  This Agreement shall be binding upon, and inure to the benefit of and be enforceable by, the Employer and its successors and assigns.  This Agreement shall inure to the benefit of Employee's heirs, legatees, legal representatives and assigns, but neither this Agreement nor any right or interest hereunder shall be assignable by Employee without the Employer's prior written consent.

	 	 	 
	
9.

	 	
Notices.  All notices, requests, demands and other communications made or given in connection with this Agreement shall be in writing and shall be deemed to have been duly given (a) if delivered, at the time delivered or (b) if mailed, at the time mailed at any general or branch United States Post Office enclosed in a certified post-paid envelope addressed to the address of the respective parties as follows:

 

	  	
To the Company:   

	
1400 Toastmaster Drive

	  	  	
Elgin, Illinois 60120

	  	  	
Attention:  Chief Financial Officer

	  	  	  
	  	
To MMI:

	
1400 Toastmaster Drive

	  	  	
Elgin, Illinois 60120

	  	  	
Attention:  Chief Financial Officer

  

8

  

	  	  	
With a copy to (which shall not constitute notice to the Employer):

	  	  	  
	  	  	
Skadden, Arps, Slate, Meagher & Flom LLP

	  	  	
155 N. Wacker Drive

	  	  	
Chicago, IL 60606

	  	  	
Attn:  Shilpi Gupta, Esq.

	  	  	  
	  	
To Employee:   

	
Selim A. Bassoul

	  	  	
6 Hubbell Court

	  	  	
Barrington, Illinois 60010

	  	  	  
	  	  	
With a copy to (which shall not constitute notice to Employee):

	  	  	  
	  	  	
Matthew E. Johnson

	  	  	
Sidley Austin LLP

	  	  	
One South Dearborn

	  	  	
Chicago, IL 60603

 

 

	  	 	
or to such other address as the party to whom notice is to be given may have previously furnished to the other party in writing in the manner set forth above, provided that notices of changes of address shall only be effective upon receipt.

	 	 	 
	
10.

	 	
Modifications and Waivers.  This Agreement may be modified or amended only by a written instrument executed by the Employer and Employee.  No term or condition of this Agreement shall be deemed to have been waived nor shall there be any estoppel to enforce any provision of this Agreement except by written instrument of the party charged with such waiver or estoppel.   The Employer’s obligations under Sections 5 and 6 of this Agreement, to the extent applicable, shall continue following the termination of Employee’s employment or the expiration of the term of this Agreement.

	 	 	 
	
11.

	 	
Entire Agreement.  This Agreement supersedes all prior agreements between the parties hereto relating to the subject matter hereof, including but not limited to the Prior Agreement, which is terminated hereby, and constitutes the entire agreement of the parties hereto relating to the subject matter hereof.

	 	 	 
	
12.

	 	
Law Governing.  The validity, interpretation, construction, performance and enforcement of this Agreement shall be governed by the laws of the State of Illinois without regard to principles of conflicts of laws.

	 	 	 
	
13.

	 	
Invalidity.  The invalidity or unenforceability of any term or terms of this agreement shall not invalidate, make unenforceable or otherwise affect any other term of this Agreement which shall remain in full force and effect.

	 	 	 
	
14.

	 	
Headings.  The headings contained herein are for reference only and shall not affect the meaning or interpretation of this Agreement.

	 	 	 
	
15.

	 	
Joint and Several.  The liability hereunder of the Company and MMI shall be joint and several.

 

 

  

9

  

 

 

	
16.

	 	
Other Agreements.  The Employer agrees to modify any and all agreements, plans and contracts as may be necessary to effectuate the terms of this Agreement; provided, however, that to the extent shareholder approval is required by applicable law or regulation to effectuate any such modification, such modification shall be subject to shareholder approval.

	 	 	 
	
17.

	 	
Section 409A.  It is intended that the payments and benefits under this Agreement comply with, or as applicable, constitute a short-term deferral or otherwise be exempt from, the provisions of Section 409A of the Code and the regulations and other guidance issued thereunder ("Section 409A").  The Employer shall administer and interpret this Agreement in a manner so that such payments and benefits comply with, or are otherwise exempt from, the provisions of Section 409A.  Any provision that would cause this Agreement to fail to satisfy Section 409A will have no force and effect until amended to comply therewith (which amendment may be retroactive to the extent permitted by Section 409A).  Notwithstanding anything contained herein to the contrary, to the extent required in order to avoid accelerated taxation and/or tax penalties under Section 409A, Employee shall not be considered to have terminated employment with the Employer for purposes of this Agreement and no payments shall be due to Employee under this Agreement providing for payment of amounts on termination of employment unless Employee would be considered to have incurred a "separation from service" from the Employer within the meaning of Section 409A.  To the extent required in order to avoid accelerated taxation and/or tax penalties under Section 409A, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to this Agreement during the six-month period immediately following Employee's termination of employment shall instead be paid on the first business day after the date that is six months following Employee's termination of employment (or upon death, if earlier).  In addition, for purposes of this Agreement, each amount to be paid or benefit to be provided to Employee pursuant to this Agreement which constitutes deferred compensation subject to Section 409A shall be construed as a separate identified payment for purposes of Section 409A.

	 	 	 
	  	 	
With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, (ii) the amount of expenses eligible for reimbursement, of in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year, and (iii) such payments shall be made on or before the last day of Employee's taxable year following the taxable year in which the expense occurred.  Any tax gross-up payment as provided herein shall be made in any event no later than the end of the calendar year immediately following the calendar year in which Employee remits the related taxes, and any reimbursement of expenses incurred due to a tax audit or litigation shall be made no later than the end of the calendar year immediately following the calendar year in which the taxes that are the subject of the audit or litigation are remitted to the taxing authority, or, if no taxes are to be remitted, the end of the calendar year following the calendar year in which the audit or litigation is completed.

 

 

  

10

  

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year first set forth above.

 

	  	  	  
	
EMPLOYEE

	  	
THE MIDDLEBY CORPORATION

	  	  	  
	  	  	  
	
/s/ Selim A. Bassoul

	  	
By

	 	
/s/ John R. Miller III

	
Selim A. Bassoul

	  	  	 	
John R. Miller III

Chairman, The Middleby Corporation Compensation Committee

	  	  	  
	  	  	  
	  	  	
MIDDLEBY MARSHALL INC.

	  	  	  
	  	  	  
	  	  	
By

	 	
/s/ John R. Miller III

	  	  	  	 	
John R. Miller III

Chairman, The Middleby Corporation Compensation Committee

 

 

  

11

  

 

EXHIBIT A

 

Illustration of Supplemental Retirement Benefit By Month

 

Based on Retirement on or After Age 55

 

	
Retirement Date (1)

	 	
Age on

February 3 (2)

	 	
Payout Per Month

as Percentage

of Retirement Salary

	 	
Aggregate Annual

Payout as Percentage

of Retirement Salary

	
February 3, 2012

	 	
55

	 	
4.167%

	 	
50.000%

	
February-12

	 	  	 	
4.167%

	 	
50.000%

	
March-12

	 	  	 	
4.184%

	 	
50.212%

	
April-12

	 	  	 	
4.202%

	 	
50.424%

	
May-12

	 	  	 	
4.220%

	 	
50.636%

	
June-12

	 	  	 	
4.237%

	 	
50.847%

	
July-12

	 	  	 	
4.255%

	 	
51.059%

	
August-12

	 	  	 	
4.273%

	 	
51.271%

	
September-12

	 	  	 	
4.290%

	 	
51.483%

	
October-12

	 	  	 	
4.308%

	 	
51.695%

	
November-12

	 	  	 	
4.326%

	 	
51.907%

	
December-12

	 	  	 	
4.343%

	 	
52.119%

	
January-13

	 	  	 	
4.361%

	 	
52.331%

	
February-13

	 	
56

	 	
4.379%

	 	
52.542%

	
March-13

	 	  	 	
4.396%

	 	
52.754%

	
April-13

	 	  	 	
4.414%

	 	
52.966%

	
May-13

	 	  	 	
4.431%

	 	
53.178%

	
June-13

	 	  	 	
4.449%

	 	
53.390%

	
July-13

	 	  	 	
4.467%

	 	
53.602%

	
August-13

	 	  	 	
4.484%

	 	
53.814%

	
September-13

	 	  	 	
4.502%

	 	
54.025%

	
October-13

	 	  	 	
4.520%

	 	
54.237%

	
November-13

	 	  	 	
4.537%

	 	
54.449%

	
December-13

	 	  	 	
4.555%

	 	
54.661%

	
January-14

	 	  	 	
4.573%

	 	
54.873%

	
February-14

	 	
57

	 	
4.590%

	 	
55.085%

	
March-14

	 	  	 	
4.608%

	 	
55.297%

	
April-14

	 	  	 	
4.626%

	 	
55.508%

	
May-14

	 	  	 	
4.643%

	 	
55.720%

  

A-1

  

	
June-14

	 	  	 	
4.661%

	 	
55.932%

	
July-14

	 	  	 	
4.679%

	 	
56.144%

	
August-14

	 	  	 	
4.696%

	 	
56.356%

	
September-14

	 	  	 	
4.714%

	 	
56.568%

	
October-14

	 	  	 	
4.732%

	 	
56.780%

	
November-14

	 	  	 	
4.749%

	 	
56.992%

	
December-14

	 	  	 	
4.767%

	 	
57.203%

	
January-15

	 	  	 	
4.785%

	 	
57.415%

	
February-15

	 	
58

	 	
4.802%

	 	
57.627%

	
March-15

	 	  	 	
4.820%

	 	
57.839%

	
April-15

	 	  	 	
4.838%

	 	
58.051%

	
May-15

	 	  	 	
4.855%

	 	
58.263%

	
June-15

	 	  	 	
4.873%

	 	
58.475%

	
July-15

	 	  	 	
4.891%

	 	
58.686%

	
August-15

	 	  	 	
4.908%

	 	
58.898%

	
September-15

	 	  	 	
4.926%

	 	
59.110%

	
October-15

	 	  	 	
4.944%

	 	
59.322%

	
November-15

	 	  	 	
4.961%

	 	
59.534%

	
December-15

	 	  	 	
4.979%

	 	
59.746%

	
January-16

	 	  	 	
4.996%

	 	
59.958%

	
February-16

	 	
59

	 	
5.014%

	 	
60.169%

	
March-16

	 	  	 	
5.032%

	 	
60.381%

	
April-16

	 	  	 	
5.049%

	 	
60.593%

	
May-16

	 	  	 	
5.067%

	 	
60.805%

	
June-16

	 	  	 	
5.085%

	 	
61.017%

	
July-16

	 	  	 	
5.102%

	 	
61.229%

	
August-16

	 	  	 	
5.120%

	 	
61.441%

	
September-16

	 	  	 	
5.138%

	 	
61.653%

	
October-16

	 	  	 	
5.155%

	 	
61.864%

	
November-16

	 	  	 	
5.173%

	 	
62.076%

	
December-16

	 	  	 	
5.191%

	 	
62.288%

	
January-17

	 	  	 	
5.208%

	 	
62.500%

	
February 3, 2017

	 	
60

	 	
5.208%

	 	
62.500%

	
February-17

	 	  	 	
5.208%

	 	
62.500%

	
March-17

	 	  	 	
5.226%

	 	
62.712%

	
April-17

	 	  	 	
5.244%

	 	
62.924%

  

A-2

  

	
May-17

	 	  	 	
5.261%

	 	
63.136%

	
June-17

	 	  	 	
5.279%

	 	
63.347%

	
July-17

	 	  	 	
5.297%

	 	
63.559%

	
August-17

	 	  	 	
5.314%

	 	
63.771%

	
September-17

	 	  	 	
5.332%

	 	
63.983%

	
October-17

	 	  	 	
5.350%

	 	
64.195%

	
November-17

	 	  	 	
5.367%

	 	
64.407%

	
December-17

	 	  	 	
5.385%

	 	
64.619%

	
January-18

	 	  	 	
5.403%

	 	
64.831%

	
February-18

	 	
61

	 	
5.420%

	 	
65.042%

	
March-18

	 	  	 	
5.438%

	 	
65.254%

	
April-18

	 	  	 	
5.456%

	 	
65.466%

	
May-18

	 	  	 	
5.473%

	 	
65.678%

	
June-18

	 	  	 	
5.491%

	 	
65.890%

	
July-18

	 	  	 	
5.508%

	 	
66.102%

	
August-18

	 	  	 	
5.526%

	 	
66.314%

	
September-18

	 	  	 	
5.544%

	 	
66.525%

	
October-18

	 	  	 	
5.561%

	 	
66.737%

	
November-18

	 	  	 	
5.579%

	 	
66.949%

	
December-18

	 	  	 	
5.597%

	 	
67.161%

	
January-19

	 	  	 	
5.614%

	 	
67.373%

	
February-19

	 	
62

	 	
5.632%

	 	
67.585%

	
March-19

	 	  	 	
5.650%

	 	
67.797%

	
April-19

	 	  	 	
5.667%

	 	
68.008%

	
May-19

	 	  	 	
5.685%

	 	
68.220%

	
June-19

	 	  	 	
5.703%

	 	
68.432%

	
July-19

	 	  	 	
5.720%

	 	
68.644%

	
August-19

	 	  	 	
5.738%

	 	
68.856%

	
September-19

	 	  	 	
5.756%

	 	
69.068%

	
October-19

	 	  	 	
5.773%

	 	
69.280%

	
November-19

	 	  	 	
5.791%

	 	
69.492%

	
December-19

	 	  	 	
5.809%

	 	
69.703%

	
January-20

	 	  	 	
5.826%

	 	
69.915%

	
February-20

	 	
63

	 	
5.844%

	 	
70.127%

	
March-20

	 	  	 	
5.862%

	 	
70.339%

	
April-20

	 	  	 	
5.879%

	 	
70.551%

  

A-3

  

	
May-20

	 	  	 	
5.897%

	 	
70.763%

	
June-20

	 	  	 	
5.915%

	 	
70.975%

	
July-20

	 	  	 	
5.932%

	 	
71.186%

	
August-20

	 	  	 	
5.950%

	 	
71.398%

	
September-20

	 	  	 	
5.968%

	 	
71.610%

	
October-20

	 	  	 	
5.985%

	 	
71.822%

	
November-20

	 	  	 	
6.003%

	 	
72.034%

	
December-20

	 	  	 	
6.020%

	 	
72.246%

	
January-21

	 	  	 	
6.038%

	 	
72.458%

	
February-21

	 	
64

	 	
6.056%

	 	
72.669%

	
March-21

	 	  	 	
6.073%

	 	
72.881%

	
April-21

	 	  	 	
6.091%

	 	
73.093%

	
May-21

	 	  	 	
6.109%

	 	
73.305%

	
June-21

	 	  	 	
6.126%

	 	
73.517%

	
July-21

	 	  	 	
6.144%

	 	
73.729%

	
August-21

	 	  	 	
6.162%

	 	
73.941%

	
September-21

	 	  	 	
6.179%

	 	
74.153%

	
October-21

	 	  	 	
6.197%

	 	
74.364%

	
November-21

	 	  	 	
6.215%

	 	
74.576%

	
December-21

	 	  	 	
6.232%

	 	
74.788%

	
January-22

	 	  	 	
6.250%

	 	
75.000%

	
February 3, 2021

	 	
65

	 	
6.250%

	 	
75.000%

	
(1)

	 	
Assumes retirement on the last day of the month.

	
(2)

	 	
Assumes 2/3/1957 date of birth

A-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]